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SUMMARY
There is evidence that blood platelets accumulate, store and 
release 5-hydroxytryptamine (5-HT, serotonin) in a manner analagous 
to the central nervous system serotonergic synaptosome. The biogenic 
amine hypothsis of affective disorders states that depression is 
associated with a deficiency of brain 5-HT. Therefore, a study was 
carried out to compare the platelet 5-HT uptake characteristics of 
platelets from depressive patients and healthy control subjects.
The rate of platelet 5-HT uptake was lower in depressive 
patients than in age and sex matched control subjects. There was no 
correlation between severity of illness and rate of 5-HT uptake, and 
the results for a group of patients tested both when depressed and 
again after recovery were similar on the two occasions. It is 
suggested that a low rate of 5-HT uptake is a trait contributing to 
a predisposition to depressive illness.
A seasonal variation in 5-HT transport was observed in both 
controls and patients. The rate of 5-HT uptake was lowest In late 
spring and early summer, which is also the time of year of greatest 
incidence of depression and the peak in the suicide rate.
Inhibition of 5-HT uptake was observed in depressed patients 
treated with either amitriptyline or zimelidine. The extent of 
inhibition of 5-HT transport was related to plasma drug concentrations, 
but did not correlate with clinical improvement.
Prophylactic treatment with lithium increased the rate of 
platelet 5-HT uptake towards normal values in both unipolar and 
bipolar patients.
The significance of these findings and their possible 
relationship to some other biochemical abnormalities observed in 
depressive patiente are discussed.
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CHAPTER ONE
DEFINITION AND CLASSIFICATION OF THE AFFECTIVE DISORDERS
The primary characteristic of the affective disorders is an 
alteration of mood to such an extent as to cause serious distress or 
disruption of normal life. The mood is elevated in mania and lowered 
in depression (Kraeplin, 1921).
An episode of depression is accompanied by one or more of the 
following symptoms. The patient complains of lack of energy and a 
loss of interest. The accustomed sleep pattern is disturbed. There 
is a loss of appetite, leading to loss of weight. The patient is 
self - reproachful and has a feeling of guilt. Anxiety is common, 
with irritability and a tendency to worry excessively over trivial 
matters. There is a loss of interest in sex and a decline in sexual 
activity. The patient may contemplate or attempt suicide.
Mania occurs less frequently than depression. The manic 
patient becomes increasingly active and is elated. He talks 
continually and loses the usual social inhibitions, becoming tactless, 
and excessively familar with strangers. Although the patient is 
cheerful he is intolerant of frustration. There is a lack of insight.
There is a reduction in sleep time, an increase in appetite, and 
excessive sexual activity (Hamilton, 1979).
• The affective disorders are commonly recurrent. The first 
episode usually occurs in the fifth decade, and if it is not treated 
it will last for 6 to 12 months and then spontaneously remit. There 
then follows a period of affective normality for several years before 
a second episode of illness. With each subsequent period of illness 
-the length of time between each episode decreases ,so that after 
several attacks the subject is suffering from affective illness for a 
considerable proportion (up to 50$) of his or her life (Coppen, 1974).
A patient is described as unipolar if he or she has had three or more 
attacks of depressive illness. A bipolar patient is one who has had 
at least one episode of depressive:illness and one episode of mania.
A patient who has had only one or two attacks of depressive illness
and has never had an attack of mania is described as monopolar (Coppen, 1970).
There is evidence that the affective disorders are of a 
familial nature (James and Chapman, 1975), and can be traced through 
several generations of the same family. The lifetime morbidity risk 
for affective disorders is higher in females than in males: Rawnsley 
(1967) quotes figures estimated for the population of London of 0.8 
and 1.4 per cent of live births for males and females respectively.
The morbidity risk for unipolar depression is about 12 per cent for 
first degree relatives of probands with unipolar depression. The 
morbidity risk for bipolar affective disorder in first degree 
relatives of bipolar probands is 16 per cent (Smeraldi, Negri and 
Melica, 1977; Trzebiatowska-Trzeciak, 1977). Leonhard (1962) 
suggested that unipolar and bipolar subjects are genetically distinct. 
This hypothc-sis is supported by several workers (Cadoret, Winokur and 
Clayton, 1970; Pardue, 1975; Perris, 1973).
THE BIOCHEMISTRY OF AFFECTIVE DISORDERS
(A) INTRODUCTION '
There are two groups of biochemical factors to be considered 
in the study of the affective disorders. Firstly, it is necessary to 
investigate changes related to the onset and duration of the illness. 
Secondly, there may be abnormalities in these patients that may make 
them vulnerable to these changes. It is therefore essential that 
patients suffering from affective disorders should be studied both 
during a period of illness and after recovery from the illness. The 
results should be compared with those obtained from control subjects, 
representative of the normal healthy population (Coppen, 1974). The 
tissues usually studied are blood and urine, but cerebrospinal fluid 
(CSF) and post-mortem brain tissue have also been investigated.
Another approach is to study the ways that drugs effective in treating 
"-affective disorders alter the biochemical functioning or composition 
of patients, normal control subjects, or experimental animals (Green 
and Costain, 1979).
There are several major difficulties which have to be considered 
when investigating the biochemistry of the affective disorders. There 
is still some controversy about the psychiatric classification of
depression, and it is difficult to measure clinical change 
quantitatively. There are difficulties in deciding whether any 
observed biochemical changes are a cause or a consequence of the mood 
change. Biochemical changes produced by a drug may be unrelated to 
its therapeutic action.
CB) THE BIOGENIC AMINE HYPOTHESIS
Ci) Indirect evidence from drug studies
The biogenic amines act as neurotransmitters in both the 
central and peripheral nervous system. There is evidence that the 
biogenic amines are involved in the aetiology of the affective disorders. 
Reserpine, an alkaloid used for the treatment of hypertension, was 
observed to produce severe depression of mood, similar to endogenous 
depression, in about 15$ of cases treated (Harris, 1957). Reserpine 
and related compounds produce a marked depletion of noradrenaline, 
dopamine and 5-hydroxytryptamine (5-HT, serotonin) from the mammalian 
central nervous system and from peripheral tissues by interfering with 
the intracellular vesicle storage mechanisms for these amines (Carlsson, 
Rosengreen, Bertler and Nilsson, 1957; Costa, Silber and Murphy, 1977).
The drug-induced impairment of the amine-binding mechanisms allows the 
amines to diffuse from the storage vesicles into the cytoplasm, where 
the amines are metabolised by intraneuronal monoamine oxidase (MAO) 
(Ivcrsen, 1973).
It was noted that the anti-tuberculosis drugs isoniazid and 
iproniazid had mood-elevating properties, and these drugs were found 
to be monoamine oxidase inhibitors (MAOI) (Zeller, 1955). Following the 
report by Crane (1956) of the antidepressant effect of iproniazid, 
several more potent and less toxic MAOI have been used as antidepressants.
These observations of the effects of reserpine and the MAOI led 
to the formulation of the biogenic amine hypothesis of affective 
disorders, according to which depression is associated with a deficiency 
of indoleamines or catecholamines, or both, and mania is associated 
with either a deficiency or an excess of biogenic amines (Pare and 
Sandler, 1959; Schildkraut, 1965; Coppen, 1971).
Pare (1965) measured the post-mortem levels of brain 5-HT in 
patients who had been given a MAOI for varying periods before they 
died, and found that the drug had to be administered for at least 2 
weeks before the levels of 5-HT in the brain tissue began to rise.
This period corresponds to the time taken for MAOI to exert their 
maximum antidepressant effect. In animals, the increase in brain 5-HT 
and catecholamines that occurs with the administration of a MAOI may 
be considerably enhanced by feeding the animal large doses of the amino 
acid which is the precursor of the monoamine. For example, a MAOI given 
with tryptophan will result in a large increase in the levels of 5-HT 
and tryptamine in rat brain (Hess and Doepfner, 1961). It has been 
reported that the antidepressant effect of a MAOI in man is enhanced 
when tryptophan is given with the MAOI (Coppen, Shaw and Farrell, 1963).
The MAOI are irreversible anzyme-inhibitors and can cause a 
near total inhibition of MAO activity in all tissues of the body, 
producing toxic side-effects. The inhibition of MAO in the gastrointestinal 
tract and liver exposes patients to the potentially toxic effects of 
dietary pressor amines such as tyramihe and B-phenylethylamine, which 
are normally metabolised by monoamine oxidase and prevented from entering 
the general circulation. Therefore patients receiving MAOI have to 
observe certain dietary restrictions.
The tricyclic antidepressant drugs such as amitriptyline and 
imipramine are potent inhibitors of the reuptake of amines at synaptic 
terminals, and they therefore increase the effective concentrations of 
monoamines at the central receptor sites, even though the total brain 
content is not increased. Although the reuptake blocking activity of 
these compounds is at present believed to be their main mechanism of 
action, the degree of reuptake inhibition does not correlate with clinical 
effectiveness (Ghose and Coppen, 1977).
Apart from their reuptake blocking activity, the tricyclic 
antidepressants possess other pharmacological properties. They have 
anticholinergic and antihistaminic properties and cause sedation. It 
is possible that the tricyclics also act as weak MAO inhibitors:
Sullivan, Dackis and Stanfield (1977) reported that blood platelet MAO 
activity - was decreased by 40$ in depressed patients after
3 weeks of treatment with either amitriptyline or imipramine. As with
the MAOI, there is some evidence that the clinical effect of tricyclic 
compounds is enhanced if given in conjunction with tryptophan (Walinder, 
et al., 1976).
(ii) Direct evidence from studies of human tissues 
(a) Neurotransmitters and their metabolites in brain
There is some evidence that 5-HT and 5-hydroxyindoleacetic acid 
(5-HIAA, metabolite of 5-HT) concentrations are lower in the brains of 
depressed patients who have committed suicide than in the brains of 
people dying from other causes (Shaw et al., 1966; Bourne et al., 1968; 
Lloyd, Farley, Deck and Hornykiewicz, 1974), although some workers have 
• not been able to replicate these findings (Beskow, Gottfries, Roos and 
Winblad, 1976; Cochran, Robins and Grote, 1976).
Studies in which catecholamine levels in: brain tissues were 
measured did not find any. differences between suicides ana controls 
in the levels of either noradrenaline or dopamine (Bourne et al., 1968; 
Pare, Young, Price and Stacey, 1969).
There are a number of factors which make it difficult to interpret 
the results of analysis of post-mortem brain tissues. Not all suicides 
are the result of depressive illness. Their nutritional state and the 
type and quantity of drugs taken before death are usually not known. *
It may be difficult to ascertain the time of day when suicide was 
committed, and it is known that many biochemical variates show circadian 
concentration variations. It has been shown that the storage time 
between death and biochemical assay can significantly affect the results 
obtained (Coppen, 1974; Beskow, Gottfries, Roos and Winblad, 1976).
Cb) Neurotransmitters and their precursors and metabolites in
cerebrospinal fluid
There have been many studies of the biochemistry of the 
cerebrospinal fluid (CSF) of patients with affective disorders.
Tryptophan has been found by some groups to be reduced in the CSF of 
depressives compared with normal controls (Coppen, 1974; Bridges, et al., 
1976), but others have reported normal CSF tryptophan levels in 
depressives (Ashcroft, et al., 1973). Several groups have reported
reduced CSF levels of 5-HIAA in depressed patients (Papeschi and McLure,
o
1971; Coppen, Prange, Whybrow and Noguera, 1972; Asberg, et al., 1975; 
Bridges, et al., 1976), but there are also reports of unchanged levels 
of CSF 5-HIAA (Vestergaard, et al., 1978). Asberg, Traskman and Thoren 
(1976) found a bimodal distribution of 5-HIAA levels in CSF samples from 
a group of 68 depressed patients. In the subgroup characterized by a 
low level of 5-HIAA in the CSF, there was a negative correlation between 
5-HIAA concentration and the severity of depression. Also, the patients 
in this subgroup attempted suicide significantly more ofter than those 
in the subgroup with normal 5-HIAA levels, and they used more violent 
means.
The CSF concentration of homovanillic acid (HVA), a deaminated 
• O-methylated metabolite of dopamine, has been found by some workers to 
be decreased in depression (Goodwin, Post, Dunner and Gordon, 1973'; 
Papeschi and McLure, 1971; Ashcroft, et al., 1973), although others 
have reported elevated levels of HVA in depression (Vestergaard, et al.,| 
1978).
Christensen and colleagues (1980) reported that the CSF 
concentration of adrenaline was significantly lower in depressed 
patients than in control subjects. When the patients were recovered 
the CSF adrenaline concentration was found to have returned to normal 
levels. No significant difference in CSF noradrenaline levels was 
found between depressive patients and control subjects.
Apart from the difficulties in evaluating this conflicting data, 
there is some dispute as to the relevance of neurotransmitter metabolite 
concentrations in lumbar CSF to neurotransnitter availability and function 
in the brain. It has been shown that in rats there is a significant 
correlation between brain tryptophan concentration and CSF tryptophan
If IT
levels (Modigh, 1975; Young, Etienne and Sourkes, 1976). Sjostrom,
Ekstedt and Anggard (1975) measured 5-HIAA, HVA, 3-methoxy-ll- 
hydroxymandelic acid (VMA, a metabolite of noradrenaline) and 3-methoxy-4- 
hydroxyphenylglcol (MHPG, a metabolite of noradrenaline) in CSF from 
four different regions along the CSF system in 17 patients. They found 
a pronounced gradient of HAV concentration, with a ratio between the 
first and last fraction of 1:7. There was a slight increase along the 
system in 5-HIAA concentration,.while HMPG and VMA showed no change.
They concluded that lumbar CSF concentrations of HVA reflect dopaminergic 
activity in the brain, but lumbar CSF concentrations of 5-HIAA and
KMPG^VMA reflect the activity of 5-HT and noradrenaline secreting 
neurones in both brain and spinal cord.
The administration of probenecid has been shown to cause an 
increase in the concentration of free tryptophan in plasma by displacing 
tryptophan from its binding sites on plasma albumin. In rats probenecid 
causes an increase in brain tryptophan concentration (Tagliamonte, et al., 
1971), but the administration of probenecid in human subjects has been 
shown to have no effect on CSF tryptophan concentration (Young, et al., 
1975). However, probenecid does cause an increase in human CSF concentra­
tions of 5-HIAA by blocking the transport of 5-HIAA out of the nervous 
system, and possibly also by causing an increase in the rate of synthesis 
of 5-HT, since the increase in free plasma tryptophan may cause an increase 
in brain tryptophan concentration which might be reflected in increased 
production of 5-HT rather than in increased brain tryptophan concentration 
alone.. It has been shown that the increase in 5-HIAA after probenecid 
is much less in depressed patients than in control subjects, which may 
be due to a reduction in 5-HT synthesis in depression (Goodwin and Post, 
1975).
(o) Amtno acid precursors of neuro-transmitters 'in blood
The catecholamines are synthesized from the amino acids 
L-tyrosine and L-phenylalanine, and 5-HT is synthesized from L-tryptophan. 
The monoamine neurotransmitters are synthesized intracellularly, 
predominantly at the nerve endings which have an active transport 
mechanism for the appropriate amino acids. The active transport of 
amino acids through the blood-brain barrier is saturable and stereo- 
specific (Pardridge and Oldendorf, 1977). The hydroxylation of tryptophan 
is the rate-limiting step in 5-HT synthesis in the brain as tryptophan- 
5-hydroxylase is unsaturated with respect to its substrate (Curzon, 1975). 
Since the synthesis of the neurotransmitters is limited in the brain by 
— amino acid availability, the rates of neurotransmitter synthesis will 
rise or fall with changes in the plasma concentration of precursor amino 
acids, and will therefore depend at least partly on_nutritional status 
(Fernstrom, 1973; Curzon and Knott, 1974). Depression is a sympton in 
certain types of malnutrition, for example, pellagra (Krishnaswamy and 
Murthy, 1970; Dickerson and Wiryanti, 1978).
The large neutral amino acids compete with each other for
transport into the brain, so that variations in the proportions of 
the various plasma amino acids may affect brain neurotransmitter 
synthesis. Furthermore, tryptophan is bound to plasma albumin 
(McMenamy and Oncly, 1958), and the free fraction is only about 20$ 
of the total plasma tryptophan. Some workers infer that only the free 
fraction is available for transport into the brain (Curzon and Knott,
1974). There are reports of lowered concentrations of free tryptophan 
in depression (Coppen, et al., 1973; Baumann,Schmocker, Reyero and 
Heimann, 1975; Kishimoto and Hama, 1976), although others have reported 
normal levels of free tryptophan in depression (Garfinkel, Warsh, Stancer 
and Sibony, 1976; Peet et al., 1976). Niskanen and colleagues reported 
higher plasma free tryptophan levels in depression (Niskanen, Huttunen,
.Ml II
Tamminen and Jaaskelainen, 1976).
The only naturally occurring class of substances which has so 
far been shown to affect the binding of tryptophan to albumin is 
nonesterified fatty acids (NEFA). jn the rat it has been found that 
plasma NEFA levels and free tryptophan concentrations are positively 
correlated (Curzon and Knott, 1974). Plasma NEFA levels are reduced 
by insulin (Manowitz, et al., 1977). As well as lowering blood glucose 
levels, insulin also causes a decrease in plasma levels of most amino 
acids, with the exception of tryptophan, which is increased (Fernstrom, 
1973). Thus, the administration of insulin, or the consumption of a 
carbohydrate meal, causes an increase in the concentration of tryptophan 
in the rat brain (Fernstrom, Larin and Wurtman, 1973; Tagliamonte, et al., 
1975). It is important, therefore, that food intake is controlled in 
laboratory animals used in experiments involving centrally-acting drugs.
9
The results obtained with human subjects vary in some instances 
from those obtained from animal studies. Lipsett observed that after 
oral glucose administration to fasting humans, the resulting release of 
insulin caused a decline in both plasma free tryptophan and plasma NEFA 
“’(Lipsett, Madras, Wurtman and Munro, 1973). Manowitz found that an 
injection of insulin administered to healthy fasting humans caused a 
decrease in plasma NEFA levels but had no effect on free tryptophan 
concentration, although there was a decrease in total tryptophan and an 
increase in other plasma amino acids. There was no correlation between 
free tryptophan and NEFA levels (Manowitz, et al., 1977). Coppen and 
Wood (1978) found that both free plasma tryptophan levels and plasma 
NEFA levels were significantly lower in depressed .patients than in
control subjects, but they did not find any correlation between free 
plasma tryptophan levels or percentage free plasma tryptophan and NEFA 
levels.
It has been suggested that the constant of tryptophan binding to 
plasma albumin approximates the apparent Km of tryptophan transport 
through the blood-brain barrier, so that albumin-bound tryptophan may 
be stripped off the plasma protein as it traverses the cerebral capillary 
bed (Pardridge and Oldendorf, 1977). Thus, if the brain's affinity for 
tryptophan is greater than that of albumin, brain tryptophan levels would 
show a better correlation with the ratio of plasma total tryptophan to 
the sum of the competing neutral amino acids that with the ratio of plasma 
free tryptophan to the sum of its competitors. It has been shown in rats 
•that a considerable fraction of albumin-bound tryptophan is stripped from 
albumin sites during a single capillary pass from blood to brain, that 
tryptophan uptake is concentration-dependent, and that amino acid competi­
tion for carrier sites is quantitatively the most important factor in 
regulating tryptophan uptake into brain (Yuwiler, Oldendorf, Geller and 
Braun, 1977). In a study of 29 control subjects, Young and colleagues 
found that the CSF tryptophan concentration correlated significantly 
and positively with the total serum tryptophan concentration, but not 
with the free serum tryptophan concentration (Young et al., 1975). There 
is general agreement that total plasma tryptophan concentrations are 
unaltered in depression (Coppen, 1974; Garfinkel, Warsh, Stancer and 
Sibony, 1976; Miller, Kirk and Fremming, 1976; Riley and Shaw, 1976; -
Niskanen, 1976), although there is at least one report of decreased total 
plasma tryptophan in depression (Baumann, Schmocker,, Reyero and Heimann,
1975).
There are conflicting reports on the plasma levels of other amino 
acids in depression. Kishimoto, Hama and Nagasaki (1978) measured plasma 
amino acid concentrations in 17 depressed patients and 15 control subjects, 
and found that of the large neutral amino acids, four were significantly 
lower in depressives (leucine, isoleucine, phenylalanine, and tyrosine) 
while two were unchanged (valine and tryptophan). Benkert measured 
plasma tyrosine concentrations only and found significantly lower 
concentrations in a group of 38 endogenous depressed patients than in a 
control group of 26 healthy subjects, though the concentrations in a 
group of }4 neutotic depressives did not differ from control values
(Benkert, Renz, Marano and Matussek, 1971). These results, if 
substantiated, would refute the argument that competition from other 
large neutral maino acids is increased in depression.
Miller, Kirk and Fremming (1976) found no difference in concentra­
tion of any of the large neutral amino acids between 19 manic depressive 
patients (18 depressed and 1 manic at time of sample collection) and 25 
healthy subjects. However, when the ratio of total tryptophan to the 
sum of the competing amino acids was examined, a small group of patients 
showed a low ratio, while the rest showed the same pattern as the controls. 
Those patients with a low ratio responded well to treatment with 
tryptophan, while those with normal ratios, with one exception, were 
resistant to tryptophan therapy. These i*esults agree with those from 
.animal experiments, which have shown the importance of the competition 
among amino acids for transport into the brain. Both tyrosine and 
phenylalanine at high plasma concentrations inhibit the passage of the 
other large neutral amino, acids into rat brain (McKean, Boggs and Peterson,
1968). Smyth and colleagues reported that high plasma concentrations 
of tyrosine caused large reductions in noradrenaline, dopamine and 5-HT 
in rat brain (Smyth, Tong and D'lorio, 1977). The increase in brain 5-HT 
concentration which follows treatments that raise brain tryptophan levels 
reflects an increase in the synthesis of 5-HT, and not a decrease in the 
release or matabolism of the monoamine, since brain levels of 5-HIAA, 
the major metabolite of 5-HT, also rise in parallel (Wurtman and Fernstrom,
1976).
(<$) Enzymes of amine metabolism in blood cells
The biogenic amines are metabolised by MAO, dehydrogenase, and 
catechol-O-methyltransferase (COMT). Blood platelet MAO activity and 
red blood cell COMT activity have both been shown to be relatively stable 
characteristics of the individual which are genetically determined 
(Leckman, Gershon, Nichols and Murphy, 1977), and any changes v/hich do 
occur are not related to clinical state (Murphy and Donnelly, 1974; Wyatt,. 
et al., 1973; Shulman, Griffiths and Diewold, 1978).
Platelet MAO activity is higher in female than in male control 
subjects (Wyatt, Potkin, Gillin and Murphy, 1978), and in the majority 
of women there is a variation in platelet MAO activity through the menstrual 
cycle, with the nadir occurring 5 to lj days after ovulation (Belmaker,
i»
Murphy, Wyatt and Lorieux, 1974; Wirz-Justice, Puhringer, Hole and Menzi,
1975). These data may relate to the higher incidence of depression in 
women than men (Robinson, et al., 1971), and to the impairment of mood 
experienced by many women during the pre-menstrual phase (Smith, 1975).
Reports of MAO and COMT activity in patients with affective 
disorders are not consistent (Gershon, .1978).' Platelet MAO activity 
has been reported as being .higher (Murphy and Weiss, 1972; Landowski, 
Lysiak and Angielski, 1975) and lower (Dunner, Cohn, Gershon and Goodwin, 
1971; Nies, Robinson, Harris and Lamborn, 1974) in bipolar patients. 
Similarly, erythrocyte COMT activity has been found to be both higher 
and lower in depressed patients (Shulman, Griffiths and Diewold, 1978).
It has been reported that MAO activity is lower in the brains of suicides 
than in the brains of control subjects (Gottfries, Oreland, Wiberg and 
Winblad, 1974).
There are difficulties in determining the relationship between 
platelet-MAO and‘central-MAO activity, for it has been shown that for 
at least some of the factors affecting. MAO activity, e.g. iron deficiency 
marked changes in peripheral-MAO activity are not reflected in central-MAO 
activity (Youdim and Green, 1977). It has been shown that the activity 
of MAO has to be very much inhibited (85$ of the enzyme in rat brain) 
before there is any appreciable effect on monoamine metabolism (Green, 
Mitchell, Tordoff and Youdim, 1977). Although it is possible that 
behavioural and mood changes may occur before there are marked biochemical 
changes, it is also possible that observed natural variations in platelet 
-MAO activity are behaviourally irrelevant.
(e) Exovetion of neurotransm'itter metabolites -in urine
Since the brain 5-HT pool is very small compared with the 
peripheral pool, it seems unlikely that meaningful information can be 
^gained by studying urinary amine metabolite excretion. This view is 
reinforced by the conflicting data obtained on indoleamine metabolite 
excretion.
There have been several studies which suggest that MHPG 
(3-methoxy-4-hydroxyphenyl glycol) is the main noradrenaline metabolite 
in the brain (Schanberg, et al., 1968). It is difficult to assess what 
proportion of urinary MHPG arises from central noradrenaline metabolism, 
although Kopin and Ebert (1974) have suggested that the proportion may
be significant, and that the predominant peripheral metabolite is VMA.
There are conflicting reports on the excretion of MHPG in depression: 
some workers have reported reduced MHPG excretion in depression 
(Greenspan, et al., .1970; Watson, Hartman and Schildkraut, 1972; Maas 
and Landis, 1968) but others have reported no difference between patients 
and controls (Bunney, et al., 1972; Coppen, et al., 1979).
(C) ELECTROLYTE BALANCE HYPOTHESIS
The interest in electrolyte balance in the biochemistry of the
affective disorders is due to a number of factors. The resting and action
potentials of nerve and muscle cells depend on inorganic ions having a
different concentration inside the cell to the concentration in the
extracellular fluid. The cell membrane is freely permeable to potassium
and chloride, but only slightly permeable to sodium. An active system
+ +
of transport of sodium, mediated by the enzyme Na/K -ATPase, maintains 
the sodium concentration within the cell at about one-tenth of its 
concentration in the extracellular fluid. The active uptake of neuro­
transmitters and their monoamine precursors is linked to the sodium/ 
potassium transport system, and is therefore dependent on the concentration 
and balance of these inorganic ions. In addition, an inorganic ion, 
lithium, has been found to be effective in the treatment of the affective 
disorders.
Schottstaedt, Grace and Wolff (1956) were the first to attempt 
to correlate changes in sodium balance with changes in mood. They 
reported that periods of depression In normal subjects were accompanied 
by a decreased urinary excretion of sodium. Using the isotope dilution 
technique to measure exchangeable sodium and potassium, Gibbons (1960) 
found that depressive patients retain sodium while depressed, but they 
excrete more sodium than normal subjects during their recovery, so that 
the total body sodium decreased to below normal in recovered patients.
_These findings have been confirmed by other workers, who have also shown 
that total body potassium is reduced in depressive patients (Coppen, 1965; 
Baer, Platmen and Fieve, 1970; Cox, Pearson and Speight, 1971). Plasma 
concentrations of sodium and potassium are normal in depressed patients, 
but there are reports of shrinkage in volume of the extracellular space 
and of total body water (Coppen and Shaw, 1963; Hullin, et al., 1967;
Cox, Pearson and Speight, 1971). Shaw, Frizel, Camps and White (1969) 
examined the fore-brains ofLdepressive suicides, and found that, compared
to a control group, the depressed group brain tissue had a higher water 
content and a low concentration of sodium. The potassium concentration 
was also low, although not statistically significant from the control 
data.
There have been a few studies of magnesium and calcium in depression. 
Flach (1964) followed the urinary excretion of calcium in depressed 
patients, maintained on a constant intake of calcium and phosphate, before 
and during recovery from their episode of depressive illness. Those 
patients who recovered showed a significant decrease in the excretion 
of calcium. Plasma calcium levels have been reported to be normal in 
depressed patients CGour and Chaudrey, 1957; Frizel, Coppen and Marks,
1969). Plasma magnesium has been reported to be both raised (Cade, 1964) 
and decreased (Frizel, Coppen and Marks, 1959) in depression.
The administration of lithium salts, which are effective 
prophylactic agents against the recurrence of depression and mania, 
cause a marked drop in exchangeable and residual sodium, but have no 
effect on total body potassium or on the urinary excretion of sodium or 
potassium (Coppen, 19.67). Keynes and Swan (1959) have shown that during 
an action potential, when sodium normally enters the cel\L, lithium and 
sodium enter the cell with equal facility, but lithium isNremoved from 
the cell at only 4 to 10% the rate of sodium. Animal studiesxshow that 
chronic lithium administration results in sodium depletion, which is 
greater in the CNS than the rest- of the body (Baer, Kassir and FieVe..
1970).
• \
* *«*
The enzyme Na*/ K -ATPase is present in high concentrations
in the brain and:'in tissues with a secretory function, such as the 
kidney. The activity of this enzyme depends on the presence of both 
sodium and potassium, and it drives the pump mechanism whereby sodium 
^and potassium are differentially distributed across the cell membrane.
- J . +
The specific activity of Na /K -ATPase in erythrocyte membranes has
been shown to be lower in depressed patients than control subjects
(Hesketh, Glen and Reading, 1977). This finding may explain the observed
disorders of sodium balance in depressed patients. Administration of
lithium to depressive patients has been shown to cause an increase in 
+  +  ' *
erythrocyte Na /K -ATPase activity (Naylor, Dick, Dick and Moody, 1974;
Sen, et al., 1976; Hokin-Neaverson, Burckhardt and Jefferson, 1976).
This finding is supported by the reports of increased uptake of biogenic 
amines during lithium adminiatration (Murphy, Colburn, Davis and Bunney,
1970; Knapp and Mandell, 1973). Thus the biogenic amine hypothesis and 
the electrolyte balance hypothesis are not separate, but are rather two 
facets of the same problem.
THE BLOOD PLATELET AS. A MODEL FOR TEE SEROTONERGIC NEURONE
As human platelets transport and store biogenic amines, clinical 
investigators have searched for platelet abnormalities that might 
correlate with various neurologic and psychiatric syndromes. Patients 
with Down’s syndrome have reduced levels of 5-HT in their platelets, 
and this has been shown to be largely due to a defect in the active 
transport of 5-HT at the platelet membrane (McCoy and Bayer, 1973). 
Phenylketonuria and histidinemia are associated with mental retardation 
and considerably diminished platelet 5-HT levels, the mechanism of 
which is not known. The levels of 5-HT are elevated in platelets from 
some patients with infantile autism. A. platelet 5-HT releasing factor 
is thought to be present in plasma during migraine headaches, and it has 
been suggested that a drop in platelet 5-HT may play a role in the 
mechanism of migraine (Anthony, 1968).' Krishnaswamy and Murthy (1970) 
found that platelet 5-HT levels were significantly lower in pellagrins 
with mental depression as compared to normal subjects, as well as to 
pellagrins whose mental status was apparently healthy. Niacin improved 
the clinical state, but caused a further reduction m  platelet 5-HT 
levels. Possibly niacin facilitates the release of 5-HT and thereby 
promotes its action at the ieceptor sites.
No consistent change has been reported in platelet 5-HT levels of 
depressed patients, but the variations between "normal” values of 
different investigators, is so great that small differences between 
patients and controls may easily have been hidden in several studies 
(Sneddon, 1973). Coppen, Turner, Rowsell and Padgham (1976) reported 
that the concentration of whole-blood 5-HT (i.e. effectively platelet 5-HT, 
"since very little 5-HT is detectable in the blood outside the platelets) 
was significantly lower during depression, but returned to normal after 
recovery. Shaw and co-workers (1971) found no difference between 
depressed patients and healthy subjects in uptake and release of 5-HT 
by platelets. Hallstrom and colleagues (.1976) measured the uptake of 
both 5-HT and dopamine by platelets from patients with various types of 
affective disorder. They found no difference in the uptake of either
amine in subjects with "neurotic" depression, but there was a significant 
reduction in the uptake of both amines in patients with "endogenous" 
depression. Tuomisto and Tukiahen (1976) reported a reduction in 5-HT 
uptake by platelets from patients with depression compared with 
platelets from control subjects.
Using blood platelets from rats, Drummond and Gordon (.1975) 
have demonstrated the presence of three types of receptors for 5-HT 
on platelets. The binding of 5-HT to one of these sites is responsible 
for the stimulatory shape change that precedes platelet aggregation in 
the clotting of blood. This receptor has low structural specificity.
A different receptor site is responsible for the uptake of 5-HT into 
the platelet, and this site has stringent structural requirements (Born, 
Juengjaroen and Michal, 1972). Bouillin has demonstrated the presence 
of at least two binding sites for 5-HT on human platelet membranes, one ’ 
with a high affinity and low capacity, and one with a low affinity and 
high capacity (Bouillin et al., 1977). Differences between control 
subjects and depressive patients in platelet 5-HT uptake might be due 
to temporary or permanent changes in either binding affinity or capacity 
at the receptor sites on platelets from depressive patients.
PURPOSE OF THIS THESIS
In many ways blood platelets act like brain synaptosomes. If 
initial rates of uptake of 5-HT are measured, the kinetics and pharma­
cology of the transport mechanism closely resemble the uptake of 5-HT 
by serotonergic neurones. In this study, the platelet was used as a 
model for the central 5-hydroxytryptaminergIc neurone.
Platelets were incubated for short periods with 14q - labelled 
5-HT, and Michaells - Menton kinetic analysis was used to determine the 
characteristics of the uptake process. The value of is an inverse 
measure of the affinity of 5-HT to bind to platelet membrane transport 
protein, and is defined as the concentration of 5-HT which is half that 
required to produce the maximal rate of transport, Vmax. The actual 
rate of uptake under experimental conditions was expressed as y, defined 
as the mean rate of uptake obtained with the different incubation 
concentrations of 5-HT. This method was also used to determine the 
characteristics of tryptophan uptake by platelets, although there is 
less evidence than for 5-HT for an analogy between this system and that
operating in the brain.
Blood platelet samples for the estimation of 5-HT and tryptophan 
uptake characteristics were obtained from drug-free depressed patients, 
drug-free recovered depressive patients and normal healthy control 
subjects. The results from the differenct groups were compared, with 
a view to discovering possible differences between controls and patients, 
and between patients before and after recovery from a depressive episode.
A deficiency in the transport system of platelets from depressive 
patients, if assumed to reflect the state of the similar transport system 
in the brain, would be further evidence in support of the biogenic amine 
hypothesis of affective disorders, since such a deficiency might lead 
to a reduced neuronal 5-HT concentration.
Platelet samples were also obtained from depressive patients 
receiving drug therapy for the treatment or prevention of depressive 
illness, in order to.'determine the effect of drug treatment. on 5-HT 
transport in vivo. It was hoped that the results may throw some light 
on the mode of action of some of the more widely used drugs, including 
a typical tricyclic antidepressant and lithium. Uptake results obtained 
before and during treatment for depression were examined for possible 
correlations with clinical state and clinical improvement. As tricyclic 
and related antidepressant drugs are thought to act by inhibiting the 
neuronal uptake of 5-HT and/or noradrenaline and dopamine, it was expected 
that the degree of inhibition of platelet 5-HT uptake would be correlated 
with clinical improvement.
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Both naturally occurring and synthetic compounds (drugs) were 
added to platelet samples in vitro, before the addition of the R e ­
labelled 5-HT> to study the effects of compounds of interest on platelet 
5-HT transport. If the platelet 5-HT uptake characteristics were found 
to be changed in depression and/or related to clinical state, this 
in vitro test system may prove to be of value in the preliminary testing 
of potential new antidepressant drugs.
Tryptophan is the amino acid precursor of 5-HT. There are 
conflicting reports on plasma levels of total and free, tryptophan in 
depressive patients. Tyrosine and phenylalanine are precursors of 
noradrenaline and dopamine. Tryptophan, tyrosine and phenylalanine are
all large neutral amino acids, and probably compete with each other for 
transport across the blood - brain barrier.
_ In this study, the plasma concentrations of tyrosine, phenyla­
lanine and total and free tryptophan were measured in samples from 
normal control subjects, drug-free depressive patients before and after 
recovery, and patients receiving antidepressant drug therapy. The 
results were examined for possible evidence of reduced availability of 
any one or all of these presursor amino acids in the blood of depressive 
patients, and the effects of drug treatment on the plasma levels. If any 
changes were found to occur with drug treatment these were tested for 
correlation with clinical improvement. The ratios between the different 
amino acids were also examined for possible differences in patients, 
which might consequently vary the competition between them for the 
transport system across the blood - brain barrier. The plasma amino 
acid levels were examined for possible correlation with platelet 5-HT 
uptake characteristics, as it is possible that any or all of them may 
compete with 5-HT for transport into the platelet.
In addition, some of the sources of within - group variations 
in platelet 5-HT uptake characteristics were examined, including the 
effects of sex, age, whether or not the subject had had breakfast, 
variations during the menstrual cycle, and the time of year of the blood 
test. A difference in results between the sexes might contribute to 
explaining the 2:1 ratio of females to males among unipolar depressive 
patients. Similarly, a seasonal variation in platelet 5-HT uptake 
would be a possible cause of the observed seasonal variation in the 
incidence of depression.
It was hoped that the work described in this thesis would 
make a contribution towards the understanding of the cause of depressive 
illness, and that the measurement of platelet 5-HT uptake characteristics 
-might prove to be of use in either the diagnosis or treatment of 
depression.
CHAPTER TWO
METHODS, AND RESULTS OF STUDIES OF CONTROL SUBJECTS
(A) BLOOD PLATELETS AS A NEURONAL MODEL
There is a severe limitation imposed on the investigator of the 
biochemistry of psychiatric disorders due to the inaccessability of the 
brain in human subjects. As yet there are no entirely satisfactory 
animal models for depression. These problems have led to a search for 
a more accessible tissue which might serve as an appropriate model for 
amine - storing neurones.
It has been suggested that blood platelets may serve as a model 
for the uptake of biogenic amines by the synaptic apparatus in brain 
tissue. This proposal is attractive for several reasons. Platelets are 
easily and repeatedly obtainable in large numbers by routine venepuncture. 
They are readily separated from other blood cells by differential 
centrifugation. Most important of all, there is strong evidence that 
blood platelets accumulate, store and release 5-HT in a manner analagous 
to the CNS serotonergic synaptosomes, and that the same drugs in similar 
concentrations affect to the same extent the uptake, storage and release 
of 5-HT in both platelets and synaptosomes (Sneddon, 1973; Stahl, 1977; 
Maitre et al., 1980).
Human blood platelets take up and concentrate 5-HT from blood 
plasma in two ways (Stacey, 1961). An active transport mechanism works 
against a concentration gradient. This transport system is saturable, 
shows structural specificity, and is reduced by metabolic inhibitors 
(Pignatti and Cavalli-Sforza, 1975). A passive transport system becomes 
evident in the cold, and at high concentrations of 5-HT in the medium 
(Jerome and Kamoun, 1970). There are at least two subcellular transport 
sites for 5-HT : the platelet mambrane and the intracellular storage 
granules, which serve to protect 5-HT from metabolism by platelet MAO.
The binding of 5-HT to the platelet membrane occurs at specific receptor
sites, and the transport of 5-HT across the membrane depends on the
+ — 
concentration of Na (Sneddon, 1969), and that of Cl (Lingjaerde, 1971).
It also depends on Na+/K+ adenosine triphosphatase (ATPase) activity.
Drummond and Gordon (1976) found that adenosine diphosphate (ADP) was a
potent non-competitive inhibitor of 5-HT uptake by rat platelets. They
+ +
concluded that ADP could inhibit 5-HT uptake by changing the Na /K
distribution across the cell membrane.
- For this thesis a study was carried out to determine the 
characteristics of platelet 5-HT uptake in both normal control subjects 
and depressive patients. The results from the different groups were 
compared, with a view to discovering possible differences between 
controls and patients.
(B) THE DETERMINATION OF 5-HT UPTAKE BY HUMAN BLOOD PLATELETS 
C'i) Methods and Materials
Blood was collected by venepuncture between 8.30 and 10.00 a.m. 
after overnight fasting, and mixed with one-tenth its volume of a 
solution containing 2 7 mM disodium ethylenediaminetetra-acetic acid (EDTA), 
120 mM sodium chloride and 6 mM glucose (Snaw et ;al_., 1971). It ^ was then 
centrifuged at 350 x g at room temperature for 10 min to obtain platelet - 
rich plasma (PRP). It was usually found to be necessary to centfifuge 
the blood samples a second time at 1,500 x g to collect extra platelet - 
poor plasma (PPP) to add to the PRP to obtain a sufficient volume of PRP. 
The concentration of platelets in the PRP was measured by diluting 50 yl
i
of PRP with 5 ml of Lempbert-Kristenson*s staining solution (Dacie, 1950), 
and counting the platelets in an aliquot of this mixture using an 
Improved Neubauer Haemacytometer.
Aliquots (0.5 ml) of PRP were preincubated for 10 min 
at either 37cC in a shaking water bath, or at 0°C in an ice-water bath, 
after which time 50 ul of 0.9$ (w/v) saline containing -Me - labelled 
5-HT (0.25, 0.5, 1.0, 2.0, and 4.0 yM, final concentration in PRP) 
(Radiochemical Centre, Amersham, U.K.) were added. The specific activity 
for all He - labelled 5-HT solutions was about 2.2 GBq/mmol. The 
"platelets were incubated for a further 2 min, then the reaction was 
stopped by the addition to each aliquot of PRP of 2 ml of ice-cold 3$
(w/v) formaldehyde in 0.9$ (w/v) saline (Costa and Murphy, 1975). The 
platelet suspensions were centrifuged at 1,500 x g at 4°C for 10. min, 
the supernatant fractions were discarded, and the inside of each tube 
wiped dry with tissue paper. Aliquots (1 ml) of 1 M KOH were added to 
each tube. The tubes were sealed with aluminium foil and "Parafilm", 
and left overnight at 37°C. Aliquots (0.2 ml) of the platelet digests
were added to 4 ml of scintillation fluid (NE 262; Nuclear Enterprises, 
Edinburgh, U.K.) and counted for radioactivity in an LKB Ultrobeta 
Spectrometer for 30 min (^C counting efficiency 90% using external 
standardization). The results were expressed as picomoles of 5-HT 
accumulated per 10^  platelets per minute. Except where stated 
otherwise, all chemicals were obtained from BDH.
Cii) Calculation: of results
The values obtained for the uptake at 0°C represent the passive 
diffusion of 5-HT into the platelets, together with the small quantity 
of 5-HT trapped between the platelets in the pellet after centrifugation. 
These figures were subtracted from the values obtained for the total 
uptake at 37°C to yie.ld the values for the active uptake of 5-KT by 
platelets. The results were then analysed in two ways. First, the 
overall uptake, y, defined by Hallstom (1976) as the mean uptake over the 
five 5-HT concentrations, was calculated. This is a measure of the 
actual uptake of 5-HT by the platelets under these experimental 
conditions. Second, the (the theoretical maximum rate of uptake)
and K^ (the concentration of 5^ -HT at which the rate of uptake is half 
the maximum theoretical rate) were determined by Lineweaver - Burk plot 
(Lineweaver and Burk, 1934). The best fit - lines for these plots were 
obtained by linear regression analysis.
The double reciprocal plot discribed by Lineweaver and Burk .
(1934) is the method of plotting which is most widely used (Dixon and
Webb, 1964). Two other popular methods of plotting^are those of
Hanes (1932) (~ against s) and Hofstee (1959) (v against -^). Results
for 10 subjects (4 control subjects and 6 depressive patients) were
re-calculated using both the Hanes plot and the Hofstee plot, but the
values obtained for K and V were not significantly different fromm max b J
those obtained using the Lineweaver - Burk plot (Table 2.1). The 
points gave slightly better straight lines for the Lineweaver - Burk 
and Hanes plots (mean correlations 0.997 and 0.999 respectively) than 
for the Hofstee plot (correlation 0.970).
Ciii) Effects on results of varying inciibation time and temperature
Lineweaver - Burk analysis requires the uptake measurements to
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be made during the initial stages of the reaction, when the rate of 
uptake is greatest, and the relationship between substrate concentration 
and rate of uptake is linear. Wielosz and co - workers (1976) 
reported that the uptake of 5-HT by human platelets was only linear 
for up to 8 min, and reached a steady state after about 15 min of 
incubation. Lingjaerde (1976), and Tuomisto and Tukiainen (1976) 
have used incubation times of 4 min to determine 5-HT uptake by 
human platelets. In the present study an incubation period of 2 min 
was chosen, as this was the shortest interval which still allowed 
sufficient time to add the 5-HT solutionsvto a set of five tubes "in 
circus". Also, errors in timing might become significant with incubation 
times of a minute or less.
In order to confirm that an incubation time of 2 min is short 
enough to satisfy the requirements of Michaelis - Menton analysis, 
samples of PRP were incubated with 0.5 yM -^ C - labelled 5-HT for a range 
of time intervals (§, 1, 2, 4, 8 and 16 min) (Figure 2.1). Each point 
is the mean of seven determinations. The uptake of 5-HT appears to be 
linear for incubation times of up to 4 min. This result agrees with 
those reported by Wielosz and colleagues (1976).
The range of concentrations of 5-HT used was from approximately 
one- half to twice the values reported recently for 5-HT uptake by 
platelets from human control.subjects (Gordon and Overman, 1976;
Lingjaerde, 1976; Tuomisto and Tukiainen, 1976; Wielosz £t al_., 1976) .
(See Table 2.2 for a comparison of results reported in the literature).
Platelet 5-HT uptake at different incubation temperatures (19,
25, 30, 34, 37 and 40°C.) was determined in one sample of PRP (Figure 2.2).
Both K and V increased at an increasing rate with increasing m max 6
Incubation temperature. There was a two-fold increase in both and
— V with a rise in temperature from 37°C to 4Q°C : it is thereforemax r
important to strictly control the.’incubation temperature when measuring 
platelet 5-HT uptake.
In experiments to investigate the effects of drugs and naturally 
occuring substances of interest, the compound to be studied was added to 
the PRP in 20 yl of 0.9% (w/v) saline, 5 min before the addition of He - 
labelled 5-HT.
Figure 2.1 Variation in platelet 5-HT uptake with incubation time
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Table 2.2
Characteristics of 5~HT uptake by platelets from control 
subjects reported in the literature
(]iM) (pmol/lO^
platelets/min)
Gordon & Olverman (1976) 1.0 120
Lingjaerde (1976) ? 0.5 100
Tuomisto & Tukiainen (1976). 10 o.U 92-
Wielosz et al. (1976) k 1.0 87
Rotman et al. (.1979) k 1.8 7°
Tukiainen & Leino (.19.80) 18 0.U : 19
Malmgren et'al. Cl980) 10 1.0 1^ 5
Arora & Meltzer (1982) k2 0.5 121
This thesis 81 0.5 kh
Figure 2.2 Effect of incubation temperature on K and VA m 1max
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(C) PLATELET 5-HT UPTAKE IN CONTROL SUBJECTS AND SOME INVESTIGATIONS
INTO POSSIBLE CAUSES OF OBSERVED VARIATIONS IN RESULTS
Ci) Normal values
In order to establish the normal range of values of platelet 
5-HT uptake characteristics in a healthy population a group of 48 
female and 33 male control subjects was studied. None of the control 
subjects had a history of psychiatric illness, and all were in good 
physical health and drug-free (with the exception of contraceptive 
hormonal preparations taken by some of the women) at the time of the 
test. The age range for the female subjects was from 17 to 66 years, 
and from 20 to 66 years for the male subjects. Blood was collected 
between 8.30 and 10.00 a.m. after overnight fasting.
There were no significant sex differences in age, platelet
concentration or platelet 5-HT uptake characteristics in the control
subjects, so the results obtained for the two sexes were combined
(Table 2.3). There were no significant correlations between platelet
concentration and age., K , V or y. Significant correlations were
m max
found between age and Vmax (r = - 0.248, p < 0.05) and between age and 
y (r = - 0.250, p < 0.05). It is therefore important that groups which 
are to be compared should be of similar age.
Hi) Comparison of anticoagulants
The values obtained for V of platelet 5-HT uptake in controlmax r r
subjects were lower than those reported by other workers (see Table 2.2). 
However, the methods used by different groups vary in several respects, 
apart from variations in incubation time mentioned above. Gordon and 
Olverman (1976) and Wielosz et al. (1976) used tri-sodium citrate as 
^anticoagulant, while other workers, including Lingjaerde (1976, 1979), used 
EDTA. Therefore a small study was carried out to compare the EDTA 
anticoagulant used throughout this project with tri-sodium citrate.
A 20 ml sample of blood was collected from each of 7 female and 
8 male control subjects, aged between 20 and 56 years. 10 ml of each 
sample was mixed with 1 ml of the usual anticoagulant (see Section B 
above), and the remaining 10 ml was mixed with 1 ml of 3.8% (w/v)
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tri-sodium citrate. Apart from the type of anticoagulant used, the 
method of platelet separation and determination of 5-HT uptake 
characteristics was the same for all samples.
For all 15 subjects the concentration of platelets in PRP was 
lower in the citrated sample than in the EDTA sample (see Table 2.4).
The anticoagulant made no difference to the value of K^ , but the 
citrated samples produced significantly higher values of ^max> "It is 
possible that the extra platelets obtained using the EDTA anticoagulant 
are a sub-population with a reduced ability to take up 5-HT.
-(%%%) Comparison of fasting and non-fasting results
At' the outset it had been decided tc ask all subjects to fast 
overnight prior to venepuncture in order to reduce the possibility 
of variations in platelet 5-HT uptake caused by dietary differences 
between subjects. However, as not everybody was willing to forgo 
breakfast (or in some cases forgot to do so) it was decided to 
investigate the effects of "breakfast" on the platelet 5-HT uptake 
results.
A group of 11 control subjects (5 female, 6 male), 
aged between 20 and 60 years, were tested on two occasions, once when 
fasting (nothing to eat or drink from midnight until after the 
venepuncture at about 9.30 a.m.), and once when not fasting (subjects- 
were requested to consume their usual breakfast). To eliminate the 
effects of seasonal variation the test-retest interyal was restricted 
to.10 weeks or less, except in the case of one female subject for 
whom the test-retest interval was 54 weeks. The consumption of breakfast 
made no difference to the results (Table 2.5a).
It was considered necessary to confirm this result, 
so the test was repeated on a group of 22 subjects who had^breakfast 
before testing and 22 subjects who fasted overnight. The subjects in 
the latter group were selected to match the non-fasting subjects as 
closely as possible for age, sex-and month of test. Again/ there were 
no significant differences between fasting and non-fasting subjects in 
platelet 5-HT uptake characteristics (Table 2.5b). However, the subjects 
who had breakfast did have a significantly higher concentration of
Table 2.1*
Comparison of anticoagulants: blood samples from 
15 control subjects
EDTA tri-sodium citrate
0
Platelet cone11 Cx 10 /ml) 2.81 + 0.21 2.08 + 0.17
K CpM) m O.kh
+ 0.03 0. UU +0.03
8V (pmol/10 pl/min)HlcU£ 1*7.9
+ 2.6 58.7* +3.5
-
— 8 y Cpmol/10 pi/min) 31.7 + 1.5
**
38.9 + 2.2
*Values significantly.different are shown . when p < 0.01 and 
when p < 0.00:1
• 
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Table 2.5b
Platelet 5“HT uptake in control subjects tested 
either with or without fasting 
Results shown as mean + S.E.M.
Fasting Not fasting
n 22 . ' ; 22
Age (yr) h3.7 ±  3-1 38.0 + 2.5
o
Platelet cone (x 10 /ml.) 2.HO +0.13
*•
3.06 + 0.18
K (jiK)m 0.50 + 0.03 0.H5 + 0.03
o
V (pmol/10 pl/min) max . HH.3 + 3.3
H5.8 + 2.8
• -
— 8 
y (pmol/10* pl/min) 28.2 + 2.2 30.3 +1.8
significantly different p < 0.01
platelets in their platelet-rich plasma. This might be due to fasting 
subjects having a lower plasma protein concentration, and hence a lower 
plasma specific gravity, so that some platelets are spun down rather 
than remaining in the platelet-rich supernatant during the preparation 
of PRP.
'Civ) Effect of delayed assay on platelet 5-HT uptake results
The incubation of PRP with - labelled 5-HT at 37°C for 
the determination of active platelet 5-HT uptake was usually carried 
out between from I to 1\ hours after venepuncture. Two small series 
of experiments were carried out to investigate the effect of delay.
In one experiment a 20 ml sample of blood was collected from each of 3 
female and 4 male subjects. 10 ml of blood was prepared as usual, with 
the PRP being incubated with - 5-HT at 1 hour after the venepuncture 
The second 10 ml of each sample was kept at room temperature and the 
preparation of PRP was commenced 1\ hour after the venepuncture. 
Similarly, 20 ml samples of blood from 3 female and 2 male control 
subjects were split, with the PRP preparation of the second half of 
each sample being delayed for 3 hours. The results (Table 2.6) 
showed that a delay in the preparation of PRP reduced the rate of 
5-HT uptake. Moreover, the amplitude of the reduction increased with 
increasing delay, being 35% when PRP preparation was delayed for 1§ 
hour, and 54% when PRP preparation was delayed for 3 hours.
In the other experiment 25 ml samples of blood were collected
from 2 fepale and 2 male control subjects, and PRP preparation carried
out immediately after venepuncture as usual. The PRP was divided into 5
sets of 0.5 ml aliquots. One set was incubated with - 5-HT at 37°C
at 1 hour after venepuncture, and one set was used for incubation with 
14C - 5-HT in an ice-water bath. The other 3 sets were kept at room
-temperature and incubated at 37°C with - 5-HT at 1§, 3 and 4§ hours
after the control set. The results showed (Figure 2.3) that delay
reduced the values obtained for V by 60 to 70%, and increased themax J *
values obtained for k by up to 350%.m
From the results of these experiments, it was clear that the 
active uptake of 5-HT by platelets should be determined as soon as 
possible after the collection of the blood sample, preferably with a
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Legend to Figure 2.3
Effect of delaying time of assay on results obtained for 5-HT uptake 
Points shown as mean with standard error bar
A higher than baseline, p < 0.05
B higher than baseline, p <  0.001, and higher than 1§ h,
p < 0.01
Vmax G lower than baseline, p < 0.01
D lower than baseline, p <0.01, and lower than 1\ h,
p < 0.001
y E lower than baseline, p <  0.001
F lower than baseline, p <0.001, and lower than lj h,
p < 0.01 '
Figure 2.3 Effect of delay of assay on platelet 5-HT uptake
50
COo
max
00o
r H
blood
drawn
14
constant interval between venepuncture and incubation of PRP with C - 
5-HT, so that the error due to the unavoidable delay caused by the time 
taken to prepare the PRP, divide it into aliquots, and preincubate for 
temperature equilibration, is constant for all samples.
(v) Effect of a metabolic inhibitor
A 20 ml sample of blood was collected from each of 5 control 
subjects. Half of the PRP obtained was used for a control determination 
of platelet 5-HT uptake, while the second half of each sample was used 
to determine the effect of ouabain, a metabolic inhibitor. Ouabain to a
-4
final concentration of 10 M was added to the aliquots of PRP 5 minutes
14before the addition of C - 5-HT. In all samples ouabain acted as a
mixed inhibitor of platelet 5-HT uptake, causing a reduction in the values
obtained for V and y, and an increase in the value obtained for K max - m
(see Table 2.7). Metabolic inhibitors, such as ouabain, are believed
to inhibit the active transport of 5-HT at the cell membrane (Pletscher,
1968). Ouabain added to PRP has been shown to cause an increase in
sodium concentration and a decrease in potassium concentration in the
platelet (Feinberg al., 1977). Thus ouabain probably inhibits
+ +
platelet 5-HT uptake by inhibiting platelet membrane Na /K ATPase 
activity.
(vi) Intraindividual variation inylatelet 5-HT uptake : effect of the 
menstrual cycle
Platelet 5-HT uptake was measured in 3 female and 4 male control 
subjects on four or more occasions. The results are shown in Table 2.8a, 
and the coefficient of variance for each subject's PRP platelet 
concentration and platelet 5-HT uptake characteristics are shown in 
Table 2.8b.
In female subjects it is possible that at least part of the
observed variation in platelet 5-HT uptake is due to variations in
hormonal status due to the menstrual cycle. The values of K ,  ,m max
PRP platelet concentration, and basal body temperature (in degrees 
Fahrenheit, measured on awakening at approximately 7 a.m. each day), 
obtained from female 1 of Table 2.8 during one cycle of 29 days, were 
plotted against day of cycle (see Figure 2.4). Basal body temperature 
gives an approximate guide to hormonal status through the menstrual 
cycle : it is lowest at ovulation, then increases as plasma progesterone
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uptake and basal body temperature during a menstrual cycle
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Day of menstrual cycle
levels rise, to reach a peak a few days before the commencement of 
menstruation (Voliman, 1974).
The values obtained for seem to approximately follow the
same cyclical pattern as basal body temperature. The correlation 
between V and temperature is high, though not significant, at
IQ3.X
r = + 0.51 (n = 12). The Vmax curve does not correspond to the pattern 
of secretion of any one of the female sex hormones during the menstrual 
cycle, and it is probably influenced by a number of interacting variables. 
Many other factors have been shown to vary according to predictable 
patterns through the menstrual cycle, including platelet MAO activity 
(Wirz - Justice et al., 1975), tyramine dose / pressor response test 
result (Ghose and Turner, 1977), plasma aldosterone and plasma renin 
• activity (Katz and Romfh, 1972), plasma amino acids CCraft and Peters, 
1971), perception (Henkin, 1974), amount of physical activity (Morris 
and Udry, 1970), and affective state (Herzberg, Johnson and Brown, 1970).
An in vitro study.of the effects of a hormone of the oestrogen
type on platelet 5-HT uptake was carried out. A 20 ml sample of blood
was collected from each of five female control subjects. Half of each
sample was used for a control determination of platelet 5-HT uptake, and
—8the other half was preincubated with 10 M oestrone sulphate for 5 win
14
before the addition of the C - 5-HT. . Oestrone acted as a non -
competitive inhibitor (Table 2.9) causing a reduction of about 50% in
the value obtained for V . -max
(vii) Effect of factors affecting water balance ,
The possibility that an individuals water and electrolyte 
balance affects the platelet 5-HT transport system was tested by adding 
the antidiuretic hormone vasopressin to PRP samples from 4 female and 
3 male control subjects, to a final concentration of 100 pUnits/ml.
This hormone caused a non-competitive inhibition of 5-HT uptake, 
reducing V fry about 40% (Table 2.10a).
A baseline 10 ml sample of blood was drawn from each of 2 
female and 3 male control subjects. Each subject then received an 
intravenous injection of 4 pg desmopressin (DDAVP, a synthetic compound 
with an effect similar to that of vasopressin). A second 10 ml sample
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Table 2.10
(a) Effect of vasopressin on platelet 5“HT uptake in vitro
n Km Vmax . y ..■ ■
6im)
O
Cpmol7l0 platelets/min)
Control T 0.56+-0.08 k5.1 + 7.8 28.0 + U.8
+ vasopressin 7 0.96 + 0.1*1 2 6.8 ..+_ .U.8 15.6* + 3.3
*
lower than own control values, p < 0.01
('b) Effect of DDAVP in vivo on platelet 5“HT uptake
n Km ymax y
(pM) Cpmol/10^ plat elet s/min)
Control baseline 5 0.^5 + 0.01+ 52.1 + 8.3 33.9 + M
+ DDAVP 5 0.39 + 0.03 50.3 + 5.6 3b. 3 ± 3.2
(c) Effect on platelet 5~HT uptake of drinking 1 L water
---
n K
(pM)
V y max 47
8Cpmol/10 platelets/min)
Control baseline 6 0.38 + 0.01+ 36.7 + U.U- 25.5 + 3.2
+ water 6 0.33 + 0.02
** ** 
b2.3 ' ±3.b 30.6 + 2.b
higher than own baseline values, p < 0.05
i
of blood was collected 3 hours after the injection of DDAVP, the subjects 
remaining fasting and thirsting until after the second venepuncture.
The results of the platelet 5-HT uptake determinations on the two sets 
of samples are shown in Table 2.10b. Contrary to the results obtained 
when vasopressin was added in vitro  ^ DDAVP had no effect on 5-HT 
transport.
A group of 3 female and 3 male control subjects gave a baseline
10 ml blood sample. Each subject then drank 1 litre of tap water, and
gave a second 10 ml blood sample lj hours later, when the circulating 
levels of diuretic hormone were assumed to have reached their maximum 
following the stimulus. The platelet 5-HT uptake results are shown 
in Table 2.10c. There was a significant increase in the rate of 5-HT 
uptake of about 15%. Thus the observed effect of natural diuretic 
hormone ex vivo was contrary to the effect of antidiuretic hormone 
in vitro.
(V'i'i'C) Effect of tryptophan3 kyniwenine^ phenylalanine and tyros-ine
The normal level of total tryptophan in human plasma is of the
order of 10 yg/ml (about 50 yM). When the intake of tryptophan is
increased as a form of antidepressant therapy (usual daily dose is 
6 gm), then the total plasma concentration increases to 30 to 40 yg/ml. 
The effect of an additional 20 yg/ml PRP on platelet 5-HT uptake wras 
determined in samples from 4 female and 2 male control subjects. The 
results are shown in Table 2.11. The extra tryptophan inhibited 
platelet 5-HT uptake, decreasing Vmax by about 30%.
Tryptophan is actively accumulated by blood platelets, although 
the affinity of the platelet transport system for tryptophan is much 
lower than the affinity for 5-HT : the Km for tryptophan uptake is 
5 to 10 yM, while the for 5-HT uptake is only 0.5 to 1.0 yM (see
this Chapter, section D). The changes in the K and V of ther J b m max
platelet 5-HT uptake caused by an additional 20 yg tryptophan/ml PRP 
are comparatively small, so it is unlikely that naturally occurring 
fluctuations in plasma tryptophan concentration caused by variations 
in diet and metabolism would significantly affect platelet 5-HT uptake 
in vivo.
Total plasma tryptophan concentrations (see this Chapter,
Table 2.11
Effect of tryptophan on platelet 5~HT uptake in vitro 
Results shown as mean + S.E.M.
n K 
m
V.max 1 ;
CpM) (pmol/10^ plat elet s /min)
Control 6 . 0.55 ± 0.11 1*3.2 ± 5.8 27.2 ± 1*.0
+ tryptophan 6 0.8U ± 0.21 30.7* + 5.7 18.1* + U.5
*
lower than own control values, p < Q.01 .
Table 2.12
Effect of phenylalanine and tyrosine on platelet 5-HT uptake in vitro
Results shown as Kean ± S.E.M.
n K m ymax 7
Cp m ) Cpmol/10^ plat elet s/min)
Control 6 0.50 ± 0.07
•
53.6 ± 3.6 3^.2 ± 1.3
+ phenylalanine 6 Q.U3 ± 0.0^ 33.0f ±  1.8 22.1f ± 1.U
+ tryosine 6 0.U8 ± 0.03 3 7 . ±  3.6 2l*.0+ ± 2.2
lower than own control value, p < 0.001
section E) were available for 19 control subjects. There was no 
significant correlation of plasma tryptophan level with either Km or 
Vmax of platelet 5-HT uptake.
Kynurenine is a quantitatively important metabolite of
tryptophan, formed by a tryptophan pyrrolase in the liver. It has
been suggested that Kynurenine may inhibit brain tryptophan uptake
(Green and Curzon, 1970). Platelets from one male control subject were
preincubated with a range of concentrations of kynurenine sulphate to
determine the effect, if any, of this compound on platelet 5-HT uptake.
At the lower concentrations of kynurenine (5 and 10 yg/ml), was not
affected (average change + 3%) while V was slightly decreasedmax
(average change - 12%). At 20 and 30 yg kynurenine/ml the decrease in
'V was greater at - 25%, while K was decreased in 18%. Thus it is max . ' m
unlikely that fluctuations in kynurenine concentration in vivo will
have any significant effects on 5-HT transport.
Phenylalanine and tyrosine, precursors of the neurotransmitter
dopamine, are both large neutral amino acids which compete with
tryptophan for transport across the blood - brain barrier. The effect
on platelet 5-HT uptake of phenylalanine and of tyrosine (extra
100 yM added to PRP) was examined in one female and 5 male control
subjects. The results are shown in Table 2.12. Both amino acids inhibited
platelet 5-HT uptake. Phenylalanine reduced the value of V „ by about
40%, and tyrosine reduced the value of V by about 30%. However,J max J
since the normal plasma concentration of phenylalanine is about 70 yM, 
and the normal plasma concentration of tyrosine is about 80 yM, it is 
unlikely that normal variations in the levels of these amino acids have 
a significant effect of platelet 5-HT uptake.
Cix) Seasonal variation in platelet 5-HT uptake
In order to investigate the possible effect of seasonal 
variation on platelet 5-HT uptake, the results obtained for platelet 
5-HT uptake in control subj ects were divided into groups according to 
the time of year when the samples were collected. A two - monthly 
interval was decided on as the smallest interval which would still 
provide suitable numbers within each group to allow for statistical 
tests to be carried out. The intervals were arbitrarily chosen as
Table 2.12
Tryptophan uptake characteristics of platelets from 
22 control subjects
Age U7.8 ±2.7 yr
Km 5.0 ± 0.5 /iM
O ;
V 1*0.7 ±  1*.7 prnol/10 platelets/min
— R
y 11.2 ± 1.0 pmol/10 platelets/min
Legend to Figure 2.5
Seasonal variation in platelet concentration and platelet 5-HT uptake 
in control subjects
Points shown as mean with standard error bar
platelet concentration A lower than July + August group,
p < 0.05
y B higher than May + June and November +
December, p < 0.05, March + April, 
p <0.01, July + August and September 
+ October, p < 0.001
C lower than November + December,
p < 0.02
V D higher than May + June, p < 0.05,
max r
March + April and September + October, 
p < 0.01, and July + August, p < 0.001
E lower than November + December, p <  0.C
F lower than July + August, p < 0.02, 
September + October, p < 0.001, and 
November + December, p < 0.01
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January + February, March + April and so on. For those control 
subjects who were tested on more than one occasion, all the results 
were included in this analysis, except when this would mean that any 
one subject was represented more than once in any one two month group.
In these cases, the most recent result was included and previous results 
omitted. In this way, a total of 116 (65 female and 51 male) platelet 
5-HT uptake results were available.
The results are shown graphically in Figure 2.5. Platelet 
5-HT uptake was found to vary according to the time of year, with the 
rate of uptake being greatest in the winter and lowest in the summer.
Thus seasonal variation in results may account for at least part of the 
intraindividual variation in results described above. These findings 
also indicate that it is necessary to test concurrently groups of 
subjects which are to be compared. •
(Dl THE DETERMINATION OF TRYPTOPHAN UPTAKE BY HUMAN BLOOD PLATELETS 
IN VITRO
Platelet - rich plasma was prepared as described in the method 
for the determination of platelet 5-HT uptake. The levels of tryptophan 
usually found in plasma are high (about 50 yM) compared with the expected 
value of for the uptake of tryptophan by platelets, so it was necessary 
to carry out the determination of platelet tryptophan uptake with the 
platelets suspended in an artificial tryptophan - free medium, rather * 
than in their autologous plasma.
» . . .
The PRP obtained from 10 ml of blood was centrifuged at 2,300 
x g at room temperature for 10 min, the supernatant fraction (platelet - 
poor plasma) was discarded, and the inside of the tube wiped dry with 
tissue paper. The platelets were resuspended by vortex mixing in a 
volume of artificial medium approximately equal to the ori_ginal volume 
"of the PRP. The artificial medium used contained 16.2 mM disodium 
phosphate, 3.8 mM monosodium phosphate, 2.7 mM disodium EDTA, 5.6 mM 
glucose, 11.0 mM sodium acetate, 104.5 mM sodium chloride and 4.0 mM 
potassium chloride, adjusted to pH 7.4 with 1 M sodium hydroxide 
(Kamoun, Lafourcade and Jerome, 1976). Aliquots (0.5 ml) of platelet 
suspension were preincubated for 10 min at either 37°C in a shaking 
water bath or at 0°C in an ice/water bath, after which time were added
1450 yl of 0.9% Cw/v) saline containing C - labelled tryptophan (0;5,
1.0, 2.0, 4.0 and 10.0 yM, final concentrations in platelet suspension)
14(Radiochemical Centre, Amersham, U.K.). The specific activity of the C 
labelled tryptophan was approximately 60 yCi/ymole, the exact value 
varying from batch to batch of tryptophan. The reaction was stopped 
after 2 min by the addition to each tube of 2 ml of ice-cold 3% 
formaldehyde in 0.9% saline (both w/v). The platelets were separated 
from the incubation medium, digested and counted for radioactivity as 
described in the method for the determination of platelet 5-HT uptake.
A group of 11 female and 11 male control subjects was studied.
The results are shown in Table 2.13. There was no significant difference 
between female and male subjects in any of the characteristics of platelet 
tryptophan uptake. There was no significant correlation between age and 
any of the platelet tryptophan uptake characteristics.
Platelet 5-HT uptake was also measured in this group of 22 
control subjects, the blood being drawn as one sample with that for the 
tryptophan uptake determination. There was no significant correlation 
between the characteristics of platelet uptake of 5-HT with those of 
platelet uptake of tryptophan.
(E) THE DETERMINATION OF'TOTAL AND FREE LEVELS OF TRIPTOPHAN 
PHENYLALANINE AND TYROSINE IN PLASMA
Tryptophan, the precursor of 5-HT, and phenylalanine and 
tyrosine, the precursors of dopamine, are all large neutral amino acids 
which probably compete with each other for transport across the blood - 
brain barrier. They may possibly also compete with 5-H.T for transport 
into the blood platelet (see Section C above).
Blood plasma samples were collected after overnight fasting, at 
the same time that blood was taken for platelet uptake experiments.
The determination of percentage - free values for tryptophan, 
phenylalanine and tyrosine were carried out within a few hours of sample 
collection. The rest of each plasma sample was stored frozen at -20°C 
until required for analysis.
Total plasma tryptophan levels were measured by a colleague
\ 
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using the method of Denkla and Dewey [1967), with the modifications 
of Wood etyal. (1977). The mean total plasma tryptophan concentration 
in a group of 12 9 control subjects was 58.3 + 0.8 yM. Plasma 
phenylalanine was determined by the method of McCaman and Robins (1962), 
as described in Sigma Technical Bulletin No. 60-F (1974). The mean 
plasma concentration of phenylalanine in a group of 93 control subjects 
was 68.4 1.4 yM. Plasma tyrosine was determined by the method of
Wong, O’Flynn and Inouye (1964), as described in Sigma Technical Bulletin 
No. 70-F (1974). The mean plasma concentration of tyrosine in a group 
of 91 control subjects was 80.9 +_ 1.5 yM.
Plasma percentage free tryptophan levels were determined by
equilibrium dialysis, using a piece of apparatus similar to that described
by Moe and Hammes (1974). This apparatus was manufactured in the M.R.C-.
Workshops, Carshalton, U.K. The chambers were separated by a single
sheet of dialysis membrane, which was previously soaked for one hour in
hot tap water, then rinsed three times in glass - distilled water (Visking
Tubing; Scientific Supplies Ltd., London, U.K.). Into one side of each
chamber was pipetted 100 pi of fresh plasma, and into the other side was
14
pipetted 100 pi of a solution consisting of C - labelled tryptophan
(2.22 MBq/ymol; approximately 2 nmol/ml; Radiochemical Centre, Amersham,
U.K.) in 0.9% (w/v) saline. The apparatus was rotated at approximately
10 rev/min for 4 h at 37°C. After equilibration, 80 yl samples were
withdrawn from each side of each chamber, and counted for radioactivity
in 4 ml scintillation fluid (NE 262) in an LKB Ultrobeta 1210 spectrometer 
14for 30 min ( C counting efficiency 90% using an external standardization). 
Radioactivity in the "saline" side of a chamber corresponds to free or 
"diffusible" tryptophan, and that in the "plasma" side of the chamber 
corresponds to free + protein-bound tryptophan. Calculation of the 
proportion of free and bound tryptophan was possible after the estimation 
of plasma total tryptophan.
It was found to be unnecessary to attempt to regulate the pH
of the samples during dialysis. The pH of 36 plasma samples was
determined using narrow range indicator paper as the aliquots were removed 
at the end of the dialysis period, and the mean pH value was 7.33 _+ 0.02.
The length of time required at 37°C for the dialysis to reach
equilibrium was determined using one sample of plasma. Aliquots were
Table 2.
Percentage free plasma tryptophan values obtained 
after various dialysis periods at 3T°C 
Results shown as mean + S.E.M. 
Coefficients of variance shown in brackets
Incubation time (h) No. of Percentage free tryptophan
.chambers
1 6 39.8 + 0.5 C3%)
2 6 2T.8 * 0.3 (.3%)
3 6 26.3 ± 0.7 Cl%)
k 6 25.b + 0.3 (3%)
5 7 26.1* ^ j.Q (io%)
loaded into 31 chambers, and samples taken for counting from several 
chambers after 1, 2, 3, 4 and 5 hours. After examining the results 
obtained (shown in Table 2.14), a period of 4 h was chosen as a 
suitable and convenient dialysis time.
The effect of freezing on plasma percentage free tryptophan was 
examined in a group of 43 samples of plasma. The group was a mixed 
one, consisting of plasma samples from 14 control subjects, 7 depressed 
patients, 12 depressive patients on antidepressant drug therapy, and 
10 drug - free recovered depressive patients. For each of these samples, 
the percentage free tryptophan was estimated by the equilibrium 
dialysis method on the day that the plasma was collected. The remainder 
of each plasma sample was stored frozen at -20°C until the repeat 
determination was carried out. The storage time ranged from 3 days 
to 34 weeks, with a mean of 13.8 +_ 1.8 weeks. The mean percentage free 
tryptophan was 27.5 +_ 0.9 for the plasma samples when fresh, and 27.7 
0.9 for the same samples after they had been frozen. There was no 
significant difference between the two sets of results when examined by 
the paired t-test. There was no significant correlation between the 
difference in percentage free tryptophan between the two determinations 
and the length of time for which the samples had been stored frozen.
There was a significant correlation between the results obtained using 
fresh plasma and the results obtained after the samples had been frozen 
(r = + 0.472, p < 0.01). Thus, if for any reason the equilibrium 
dialysis determination of percentage free tryptophan cannot be carried 
out on the same day that a plasma sample is collected, it is acceptable 
to store the sample at -20°C for the estimation to be carried out at 
a more convenient date.
The equilibrium dialysis method was also used for the determination 
of plasma free tyrosine and plasma free phenylalanine levels.
^Percentage free tyrosine was determined in 14 samples of plasma, and 
was found to be 100% free in all cases. This result agrees with the 
generally held view that plasma amino acids (with the exception of tryptophan) 
are not appreciably bound to plasma proteins. Percentage free 
phenylalanine was determined in 27 plasma samples, and was found to be 
only 90.5 +_ 0.4% free, i.e. about 10% of phenylalanine In these samples 
was bound to plasma proteins. This is contrary to the generally accepted
view, and is possibly worthy of further investigation.
The equilibrium dialysis method was also used to measure
drug binding to plasma proteins in depressed patients treated with
3 . . .  3zimelidine, using H-labelled zimelidine and H-labelled norzimelidine
(gifts of Astra Ltd.).
CHAPTER THREE
PLATELET UPTAKE OF 5-HT AND TRYPTOPHAN, AND PLASMA CONCENTRATION OF 
TRYPTOPHAN, TYROSINE AND PHENYLALANINE, IN DEPRESSIVE PATIENTS
(A) PATIENTS
Platelet 5-HT uptake characteristics were determined for 50 
female and 27 male depressed patients. All were patients at the 
Clinical Investigation Ward of the MRC Neuropsychiatric Research 
Laboratory, West Park Hospital, and the majority were in-patients.
All were diagnosed as suffering from primary depressive illness 
(Medical Research Council Clinical Psychiatry Committee, 1965), and 
none had a history of mania. The patients remained drug-free (with 
the exception of hypnotics;for night sedation where necessary) and 
received supportive psychotherapy for 7 to 10 days before testing.
At the end of tfiis drug-free period the patients were assessed for 
the severity of their depressive illness using the first sixteen items 
of the Hamilton Rating Scale for depression (HRS; Hamilton, 19C7). The 
HRS assessments were made by two independent assessors who showed a 
satisfactory concordance (r = + 0.98, p < 0.001), and the mean HRS score 
was recorded. A HRS score of 16 or more was considered to indicate 
moderate to severe depression, 7 to 15 mild depression, and patients 
scoring 6 or less were regarded as clinically recovered. Patients were 
also assessed by the Newcastle rating scale (Carney et_ al_., 1965), on 
which a high score indicates an endogenous depression and a low score 
a non-endogenous (reactive or neurotic)depression.
At the end of the drug-free period, and when possible on the 
same day that HRS assessments were made, blood for the estimation of 
platelet 5-HT uptake characteristics was collected. The sample was 
— obtained by venepuncture between 8 a.m. and 10 a.m., with the mimimum 
of stasis, after overnight fasting.
Platelet 5-HT uptake was also determined for 24 female and 9 
male recovered depressive patients. These patients had all been 
admitted to hospital suffering from primary depressive illness and had 
been treated either with an antidepressant drug (amitriptyline, 
cyclazindole or zimelidine) or by ECT. The medication was then withdrawn
in those patients who had recovered, and after a further 14 days 
without antidepressant drug treatment their clinical state was 
assessed.
Those patients with a HRS score of 6 or less were regarded as 
recovered.
For comparison with the depressive patients, a group of 48 
control subjects was selected from those described in Chapter 2, 
omitting results from those aged 35 years or less.
(B) RESULTS
(i,). Platelet S-RT uptake in depressive patients
• The Vmax of platelet 5-HT uptake was found to be significantly 
lower than control values in both depressed (p < 0.05) and recovered 
depressive patients (p <0.001) (Table 3.1). The recovered patients 
had a lower than the depressed patients (p < 0.00.1). The value
of Km was almost the same for all three groups. Both groups of patients 
had a significantly higher concentration of platelets in the PRP than 
the control subjects (p < 0.05).
Hamilton rating scores were available for 65 of the depressed
patients. The range was from 7 to 32. There was no significant
correlation between HRS and age, PRP platelet concentration, K , Vb 9 r • m* max
o.r y.
Newcastle classification scores were available for 67 of the
depressed patients. Since the Newcastle rating is an interval measure
it cannot be used for product - moment correlations. Therefore, the
results for these patients were divided into three groups corresponding
to Newcastle ratings of 0 to 3, 4 to 6, and 7 to 11. There were no
significant differences between the three groups in PRP platelet
concentration, K , V or y (Table 3.2). The patients with a Newcastle m max
rating between 7 and 11 were significantly older (p < 0.02) than those
with a rating between 0 and 3, but this is probably due to older
patients being more likely to have had a previous episode of depression, 
which adds 1 to the Newcastle rating. Alsothe average age of onset
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Table 3 .2
Platelet 5~HT uptake of depressed patients divided 
according to Newcastle classification 
Results shown as mean + S.E.M.
0 to 3  ^to 6 7 to 11
n 21 28 18
Age (yr) UT.6 +,2.7 53.1 + 2.3 57.7* +3.0
o
Platelet cone11 Cx 10 /ml) 2.85 + 0.22 -2.87 + O.llr 3.09+0.20
*K (]iM) m 0.50 ± o.oU 0 1 
+ 0.03 0.62+0.09
• Vmax Cpmol/103 pi/min) 31.3 + 2.3 30.3 + 2.k 36.7 + 3 .o ’
— 8 y (pmol/10 pi/min) 20.3 + 1.6 19.9 + 1.5 22.6 + 1.8
*
older than 0 to 3 group, p < Q.02
of neurotic depression is lower than that of endogenous depression.
In order to investigate further the possible relationship 
between clinical state and platelet 5-HT uptake, a group of 16 patients 
tested.when severely depressed (HRS of 16 or more) were re-tested after 
recovery (HRS of 6 or less). Clinical state was found to have no 
effect on platelet 5-HT uptake (Table 3.3).
Since clinical state did not appear to affect platelet 5-HT 
uptake, results for depressed and recovered patients were combined 
for the purpose of analysis for seasonal variation. Any one patient 
was included only once in any 2 - month sample : where depressed and 
recovered results were obtained within the same 2 - month period, the 
recovered result was omitted. This was only the case for 2 patients, 
so that 108 results were available.
The PRP platelet concentration, and Vmax and y of 5-HT uptake
were found to vary according to the time of year of testing (Figure 3.1).
Both V and y were lowest In May and June, which coincides v’ith the max J .
time of year when the Incidence of depression is greatest. There was 
no significant seasonal variation In K '.
The seasonal variation in Vmax in depressive patients is similar 
to that found in control subjects (Chapter 2,'Figure.2.5).■■ However, the 
trough in the V ^  curve for patients occurs in May and June, while the 
trough for controls occurs in July and August (Figure 3.2). Hence, the 
controls have significantly higher values of Vmax than patients during 
Winter and Spring, but from July to October the two groups have very
similar values of v. max
Since depressed patients often suffer from sleep disturbances,
~— -they frequently require or demand night sedation. When this project
was commenced it was generally believed that the commonly administered
hypnotics have no effect on neurotransmitter transport processes. Thus
many of the depressed patients were receiving hypnotics when platelet
5-HT uptake estimations were made. By chance it was found that patients
receiving nitrazepam in addition to lithium had significantly lower
values of V_„„ than patients receiving only lithium (Chapter 5, Table 5.8). max
It proved difficult in many cases to find out retrospectively, in some
Table 3 .3
Platelet 5~HT uptake in 16 patients tested before and 
after recovery from a depressive episode
Results shown as mean + S.E.M. -
; Depressed Recovered
o
Platelet cone (x 10 /ml) 2.78 + 0.19 2.99 + 0.19
K (yM) .. 0.52 + 0.05 0.50 + O.OU.m — . —
o
V (pmol/10 pl/min) 26.0 1+.0 26.9 + 3.7max
—  ft
y (pmol /.10 pl/min) 16.6 +^2.6 17*2 _+ 2.h
Legend to Figure 3.1
Seasonal variation in platelet concentration and platelet 5-HT uptake 
in depressive patients
Points shown as mean with standard error bar
Platelet concentration A lower than January + February, July +
August, September + October, and 
November + December (p < 0.05)
y lower than July + August and November 
+ December (p < 0.02) and September 
+ October (p < 0.01)
Vmax
C lower than January + February (p < 0.05) 
July + August (p < 0.02), September + 
October and November + December Cp < 0.01)
Figure 3.1 Seasonal variation in platelet 5-HT uptake in 
depressive patients
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cases several years after testing, whether or not a depressed patient 
otherwise drug-free, was receiving night sedation. Definite information 
was available for 42 depressed patients, of whom 15 were completely 
drug-free, 5 were receiving chloral hydrate, 6 were on triazolam 
("Halcion"), and 18 were on nitrazepam ("Mogadon”). Chloral hydrate 
and triazolam appeared to have no effect on platelet 5-HT uptake 
characteristics, but patients receiving nitrazepam had a lower V ^
' (Table 3.4).
L-tryptophan,the precursor of 5-HT. has been used in the treatment 
of depression. In the doses usually used (3 to 8 gm/day), the plasma 
total tryptophan concentration is raised 3 - fold, from about 50 pM to 
about 150 y'w. Extra tryptophan, to a final concentration of 100 yM, was 
added to PRP samples from 6 patients, prior to the addition of *^ C - 5-HT.
In vitro extra tryptophan was found to cause a small but significant 
(p-< 0.01) reduction in Vmax and y (Table 3.5). This is similar to the 
result obtained when tryptophan was added in vitro to PRP from control 
subjects (Chapter 2, Table 2.10).
Hi) Plasma concentrations of tryptophan, phenylalanine and tyro sine 
in depressive patients.
Plasma total tryptophan concentration (determined by a colleague), 
percent free tryptophan (determined by the equilibrium dialysis method), 
and plasma free tryptophan concentration were measured in plasma samples 
from 25 control subjects, 15 depressed patients and 19 recovered depressives 
There were no significant differences between the groups in these 
comparatively small samples (Table 3.6).
Phenylalanine and tyrosine, both, of which are large neutral amino 
acids which probably compete with tryptophan in transport systems,
— -together with total tryptophan were determined in plasma samples from 
50 control subjects, 43 depressed patients, and 27 recovered depressive 
patients. There were no significant differences between the groups in 
any of the three amino acid concentrations (Table 3.7). The ratios were 
claculated for each of these samples of tyrosine to tryptophan, 
phenylalanine to tryptophan, and phenylalanine to tyrosine; and of 
tryptophan + tyrosine to phenylalanine, tryptophan + phenylalanine to
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Table 3. 5
Effect of tryptophan on 5-HT uptake by platelets from 
6 depressive patients 
Results shown as mean + S.E.M.
• • Patients1 PRP Patients' PRP 
+ extra tryptophan
.■ V . K GjM) 
m O.kk + 0.03 0.51 + 0.0U
V--„ Cpmol/108 pl/min)ILcLX 19.6 ± 2.k 11.3*' + 0.8
— 8 
y (pmol/10 pl/min) 12.9+1.5 7.2 * 0.^
p < 0.01 (method of paired comparisons)
Table 3.6
Total, percent free and free plasma tryptophan (.try) in 
control subjects, depressed patients, and recovered
depressives 
Results shown as mean + S.E.M.
Group n Total try (pM)
i
% free
«
Free try (pM)
Controls 23 55.3 + 2.0 27.1 + 1.3 1U.8 ±0.8
Depressed 15 ' 52.k +1.5 25.1 ±  1.5 13.0 ±  0.7
Recovered 19 53.9 ±1.5 25.1 ±  1.5 13. ^  ±  0.7
*
Value calculated using total tryptophan concentrations and 
percent free tryptophan results.
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tyrosine, and tyrosine + phenylalanine to tryptophan. There were no 
differences between the groups in any of the amino acid ratios.
Plasma total and free tryptophan concentrations determined in 
samples from 129 control, subjects and 106 depressed patients were available 
for analysis for seasonal variation. The determinations were carried out 
by several colleagues, using an ultrafiltration technique for the 
determination of free tryptophan.
In both controls and patients there was significant seasonal 
variation in both total and free plasma tryptophan concentrations 
(Figure 3.3). Total tryptophan was lowest in January and February and 
in September and October in both groups; and was highest in March and 
April and in November and December in controls, and highest in May and 
June and November and December in depressed patients. Although total 
tryptophan concentrations were higher in the patients than in the controls 
at all times, the difference only reached significance (p < 0.01) in 
May and June. "
Plasma free tryptophan showed two distinct peaks in controls in 
March and April and at the end of the year, whereas there was only one 
distinct peak in free tryptophan in the depressed patients, In May and 
June. The pattern of variation in the controls was the reverse of that 
in the patients, so that the controls had significantly higher levels of 
free tryptophan than the patients in the Spring and Autumn. Conversely, 
the free tryptophan levels in the two groups were almost identical in 
January, February and May and June. Investigations carried out during 
these months could be expected to fail to show any significant difference 
between depressives and controls. This may account for the lack of 
agreement in results presented by different groups. The troughs in 
the concentration of free plasma tryptophan in depressed patients that 
occur in Spring and Autumn correspond to the peaks in the seasonal 
variations that have been described in the incidence of affective 
disorders (Eastwood and Peacocke, 1976, Lester, 1979).
Plasma phenylalanine concentrations in 93 controls, 58 depressed 
patients and 36 recovered depressive patients were available for analysis 
for seasonal variation. In all three groups, the plasma concentration of 
phenylalanine was lowest in May and June. Only in the recovered depressives
Legend to Figure 3.3
Seasonal variation in plasma tryptophan in control subjects and
depressive patients
Points shown as mean with standard error bar
*
Controls and patients significantly different where p < 0.01,
p < 0.001
Total tryptophan : patients A
B
Total tryptophan : controls C
D
Free tryptophan : patients E
Free tryptophan : controls F
lower than May + June and 
November + December (p < 0.05)
lower than May + June and 
November + December (p < 0.001)
lower than March + April (p ;< 0.02) 
and November + December (p < 0.01)
lower than March + April (p <0.01) 
and November + December (p < 0.001)
lower than May + June (p <0.05)
lower than January + February
(p < 0.05) and May + June (p < 0.01)
higher than January + February
(p < 0.05) and May + June (p < 0.01)
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Figure 3.3 Seasonal variation in plasma tryptophan concentrations 
in control' subj ects and depressive patients
TOTAL TRYPTOPHAN
PATIENTS
60
58
CONTROLS
7.0- FREE TRYPTOPHAN CONTROLS
6.0
PATIENTS
1r
J+F M+A M+J J+A S+0 N+D J+F
Month of test
was there any significant difference between the lowest level (56 yM) in 
May and June and the highest level (74.5 yM), which in this group 
occurred in November and December (p < 0.05).
Plasma tyrosine concentrations in 89 controls, 56 depressed 
patients, and 36 recovered depressive patients were available for 
seasonal analysis. In none of the groups was there any significant 
seasonal variation.
The ratio to the plasma phenylalanine concentration to plasma 
tyrosine concentration was calculated for 87 control subjects, 55 
depressed patients, and 35 recovered depressive patients. In all three 
groups the ratio was low in May and June. In the recovered depressives 
. there was a significant difference between the ratio in May and June (0.80) 
and the ratio in November and December (1.06) (p < 0.02). The lowest 
ratio in controls was obtained in November and December (0.77), and this 
was significantly lower than the peak (0.92) in September and October 
(p <0.02). There was a significant difference in the ratio between the 
controls and the recovered depressive patients in November and December 
(P < 0.01).
(i'Li) Platelet tryptophan uptake
Platelet tryptophan uptake characteristics were determined for 
20 depressed patients and 11 recovered depressives. There were no - 
significant differences in or Vmax between the groups. The depressed 
patients had a significantly higher platelet tryptophan uptake than 
controls, as indicated by the value of y (p < 0.05) (Table 3.8).
(C) DISCUSSION
The rate of platelet 5-HT uptake was found to be significantly 
lower in depressed patients than in control subjects. This finding 
is in agreement with other reports (Tuomisto, Tukiainen and Ahlfors,
1979; Malmgren et al., 1983). The reduction in platelet 5-HT uptake 
in the patients was independent of clinical state. The rate of uptake 
of 5-HT was found to remain low in patients who had recovered from an 
episode of depressive illness. Therefore it is concluded that the 
low rate.of platelet 5-HT uptake observed in depressive patients is 
a trait which contributes to a predisposition to depressive illness.
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When the platelet 5-HT uptake results obtained for the depressed 
patients were divided into three groups according to the Newcastle 
ratings of the patients, no significant differences were found between 
the groups. Thus both endogenous and non-endogenous depressed 
patients have a reduced rate of platelet 5-HT uptake. Therefore, 
this biochemical assay is of no assistance in the classification of 
depressive illness into the widely used categories of endogenous and 
nonr-endogenous or reactive.
A seasonal variation in the rate of platelet 5-HT uptake was 
observed in both control subjects and depressive patients. The rate 
of uptake was lowest in late spring and early summer, which is also 
the time of year when the incidence of depression and of suicides is 
•greatest (Eastwood and Peacocke, 1976; Lester, 1979; Bazas et al.,
1979). Thus a seasonal reduction in the rate of 5-HT uptake contributes 
to the observed increase in vulnerability to depressive illness.
The finding of a seasonal variation in platelet 5-HT uptake also 
emphasises the necessity to test concurrently groups of subjects who 
'are to be compared.
Although the addition to PRP of comparatively large amounts of 
tryptophan, kynurenine, phenylalanine and tyrosine caused inhibition 
of platelet 5-HT uptake, it is unlikely that natural variations in vivo 
have any significant effect on the rate of 5-HT transport. Tryptophan 
administered in therapeutic doses, which cause a 3-fold increase in * 
plasma tryptophan concentration, may be expected to cause a slight 
degree of inhibition of 5-HT uptake if the results obtained in vivo 
reflect the effects observed in vitro. Thus in addition to increasing 
brain 5-HT synthesis tryptophan in therapeutic doses may also act 
in a similar way to the tricyclic antidepressants by inhibiting the 
re-uptake of 5-HT.
Depressed patients were shown to have a higher rate of uptake 
of tryptophan by platelets than control subjects. If this increased 
rate of tryptophan transport is reflected in the brain, and if the 
uptake is only of unbound tryptophan, this may indicate a compensating 
mechanism, since depressed patients have lower levels of plasma free 
tryptophan than control subjects. A higher rate of tryptophan uptake 
in depressed patients would lead to a restoration of the net accumulation
tryptophan by the brain to normal.
CHAPTER FOUR
THE EFFECT OF TREATMENT WITH ANTIDEPRESSANT DRUGS 
ON PLATELET 5-HT UPTAKE
THE EFFECTS OF AMITRIPTYLINE AND ZIMELIDINE ON PLATELET 5-HT UPTAKE 
IN DEPRESSED PATIENTS.
A clinical trial was carried out to compare the efficacy of 
a new drug, zimelidine, with that of a well-established tricyclic 
antidepressant, amitriptyline, in the treatment of depressive illness. 
In order to compare the effects of the two drugs as inhibitors of 
5-HT uptake, the. platelet 5-HT uptake characteristics of the patients 
were determined before and during treatment. Possible relationships 
between 5-HT uptake inhibition, clinical outcome and plasma drug 
concentrations were Investigated for both amitriptyline and zimelidine.
(A) INTRODUCTION TO DRUGS STUDIED
CD Amitvipty Vine
A comprehensive review by Morris and Beck (1974)showed that 
in 85 controlled trials comparing 93 treatment groups, tricyclic 
antidepressant drugs were superior to placebo in 60, and indistinguishable 
in 31. In no case was placebo superior in a controlled investigation.
Thus, 65 to 70% of all depressed patients who receive a tricyclic drug 
are likely to benefit.
Amitriptyline, a typical tricyclic antidepressant, is a dimethylated 
tertiary amine with anticholinergic and antihistaminic actions. It 
also possesses mild tranquillising properties (Wade and Reynolds, 1977). 
_Tricyclic antidepressant drugs are very potent inhibitors of the reuptake 
of biogenic amines at synaptic terminals. They therefore increase the 
effective concentrations of monoamines at central receptor sites, even 
though the brain amine content is not increased. This effect is thought 
to be the means by which they exert their antidepressant action. 
Amitriptyline is a potent inhibitor of 5-HT uptake (Kannengiesser, Hunt 
and Raynauld, 1973), while its desmethyl derivative, nortriptyline, 
strongly inhibits the uptake of noradrenaline (Carlsson et al(J 1969).
At higher concentrations, amitriptyline also acts as an a - adrenoreceptor 
blocker.
In blood, amitriptyline and nortriptyline bind to plasma
proteins to a large extent CBorga and Lundi, 1970), so that renal
excretion of the drug Is slow. Only 30% of the ingested dose appears
in the urine during the first 24 hours following an overdose (Card et al.,
1973). Hence, amitriptyline has a long plasma half-life of 25 to 40
hours CBraithwalte and IViddop, 1971; Jorgensen and Staehr, 1976).
Amitriptyline has to be administered for from 3 to 4 weeks before the
full therapeutic benefit is achieved. The optimum plasma levels which
produce the best clinical response lie within the range 50 to 140 ng/ml :
both very low and very high levels produce little or no therapeutic 
o
benefit (Asberg et al., 1971).
In vitro studies show that amitriptyline and nortriptyline are
-90 - 95% bound to plasma albumin (Borga/ et al., 1969). During treatment
with nortriptyline, the ratio of CSF nortriptyline to the total level in
the plasma was found to be on average 7%, with a two-fold variation
between individuals QCragh-Sorensen et al., 1976) : this figure is
assumed to represent the proportion of unbound drug in the plasma, which
is probably in equilibrium with the CSF. In a World Health Organization
study involving 54 depressed patients, no correlation of importance was
found between clinical Improvement and pllasma levels of amitriptyline
or nortriptyline CCoppen et al., 1978). However, attempts to relate
clinical and pharmacological effects of tricyclic drugs with their plasma
levels in vivo have generally relied; on measurements of total drug
levels in the plasma. Since it Is possible that only the free fraction
is pharmacologically active, any correlations may lose significance
because of variability In the degree of binding between individuals.
The differences between individuals in the degree of protein binding of
tricyclics has been shown to be partly under genetic control, partly
o
subject to environmental Influences (Alexanderson and Borga, 1972), and
o
dependent on plasma albumin concentration CBorga et al., 1969). 
tii) Zimelidine
Zimelidine Is a two ring compound derived from pheniramine. In 
rat brain slices both zimelidine and norzimelidine, its desmethylated 
secondary amine metabolite, have been shown to be powerful inhibitors 
of the neuronal reuptake of 5-HT, and to a very much lesser extent of 
noradrenaline (Ross and Renyi, 1977). After oral administration to rats,
zimelidine Is about 7 times more potent than chlorimipramine, and about 
J.2 times more potent than Iraipramine in inhibiting 5-HT uptake (Ross 
and Renyi, 1973). In studies in mice, zimelidine strongly potentiated 
the behavioural effects of 5-hydroxytryptophan but only weakly potentiated 
the effects of L-dopa : this Is further evidence that zimelidine has a 
strong effect on the uptake of 5-HT, but only a weak effect on noradrenaline 
uptake (Ogren, 1973)^ . In animal tests zimelidine showed only weak antic­
holinergic effects COgren, 1973).
On the basis of Its effects in animals, it might.be expected that 
zimelidine would have important antidepressant properties, but may lack 
the unpleasant anticholinergic side-effects commonly associated with 
tricyclic antidepressant drugs such as amitriptyline. Clinical studies 
have confirmed the pharmacological profile (Siwers et al., 1977), and 
the results of an open study suggested that zimelidine has an antidepressant 
action (Benkert et al., 1977).
(B.) PATIENTS
The in-patients studied were all diagnosed to be suffering from 
primary depressive illness (Medical Research Council, 1965), and none 
had a history of mania. The patients remained drug-free and received 
matched placebo capsules and supportive psychotherapy for 7 to 10 days 
before active drugs were administered. No other medication apart from 
nitrazepam (maximum dose 10 mg daily) was allowed.
At the end of the drug-free period the patients were assessed for 
the severity of their symptoms using the Hamilton Rating Scale (HRS) for 
depression (Hamilton, 1967). Only those patients who scored 16 or more 
on the first 16 items of the HRS were included in the study. Nine male 
and 17 female patients, aged between 25 and 77 years, were randomly 
allocated to receive either amitriptyline or zimelidine. The sex ratio, 
mean age, and mean baseline Hamilton Rating score of both groups were 
similar (Table 4.1). The patients received either 75 mg amitriptyline or 
100 mg zimelidine in a single evening dose for the initial 3 days. For 
the remainder of the trial period of 6 weeks they received an additional 
capsule in the morning. Thus, the patients received either 150 mg 
amitriptyline or 200 mg zimelidine per day. The trial was carried out 
using double-blind conditions, so that neither the patients, medical staff
. 
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nor laboratory staff knew which drug any particular patient was receiving.
Severity of the patients’ depression was assessed using the 
Hamilton rating scale at the end of the drug-free period (baseline) and 
after 2, 4 and 6 weeks of active drug treatment. Clinical change during 
active treatment was expressed in three ways :
1. The Hamilton rating score after 4 and 6 weeks of treatment;
2. The percentage improvement on the Hamilton score from the 
baseline to the 4 and 6 week scores;
3. The amelioration score, i.e. the change in Hamilton rating 
from the baseline to the 4 and 6 weeks scores.
The subjective side-effects of the drug treatments were assessed 
by asking the patients to complete a standardized side-effects inventory 
(Ghose, 1977) at baseline, and after.1, 2, 4 and 6 weeks of treatment.
The subjective side-effects scores at baseline were deducted from the 
side-effects scores obtained on active medication to obtain a corrected 
side-effects score.
Plasma drug concentrations were determined at baseline, and after 
1, 2, 4 and 6 weeks of treatment. Blood samples were drawn from the 
patients at about 9 a.m. after an overnight fast, i.e. about 13 hours \ 
after the last drug intake and before the morning dose. The plasma was 
separated and stored frozen until required for analysis. Amitriptyline 
and nortriptyline plasma levels were determined by a gas chromatographic 
method (J^rgenen, 1975). Plasma concentrations of zimelidine and 
norzimelidine were determined by high performance ion-pair partition 
chromatography (Westerlund, unpublished report, 1976). In 9 patients 
the non-bound (free) percentage of zimelidine and norzimelidine were 
determined by equilibrium dialysis. This was performed on fresh plasma 
after 4 weeks of treatment.
Blood samples for the estimation of platelet 5-HT and tryptophan 
uptake characteristics, and plasma levels of tryptophan, phenylalanine, 
and tyrosine, were collected at baseline and after 4 weeks of active drug 
treatment. Blood was obtained from the patients, who had fasted overnight, 
by venepuncture between 8.30 and 9.30 a.m., with the minimum of stasis.
(C) RESULTS
(i) Clinical response and effect on platelet 5-HT uptake of amitriptyline 
and zimelidine.
There was no significant difference between amitriptyline and 
zimelidine in their antidepressant efficacy. Hamilton rating scores 
- in the two treatment groups were similar at 2, 4 and 6 weeks (Table 4.2). 
However, while the amitriptyline group showed a relatively small positive 
corrected side-effects score, the zimelidine group showed a significant 
decrease from the baseline side-effects scores after 6 weeks. Thus, 
as was predicted from animal tests, the virtual absence of anticholinergic 
effects by zimelidine results in fewer unpleasant side-effects, so that 
in this respect zimelidine f5. a superior treatment when compared with 
typical antidepressants such as amitriptyline.
Both am.itriptyline and zimelidine caused a large and significant
reduction in platelet 5-HT uptake (Table 4.3). Both drugs acted as
competitive inhibitors in 5-HT uptake, as they each caused an increase
in K but had no significant effect on the value of V . Zimelidine wasm. 6 max
a stronger inhibitor of 5-HT uptake than amitriptyline. The value 
obtained for patients receiving zimelidine was significantly higher than 
that obtained for patients receiving amitriptyline. The inhibition of 
uptake as indicated by the decrease in the value of y was greater in
patients on zimelidine (63% lower than baseline) than in patients on
amitriptyline (36% lower than baseline).
No significant correlation was found between clinical response
after 4 weeks of treatment and platelet 5-HT uptake in either treatment
group. There was no correlation between 4 week values of K , V and y & r m max J
with Hamilton rating score, amelioration score or percentage improvement, 
.neither was there any correlation between the change from baseline or the 
percentage change from baseline in platelet 5-HT uptake characteristics 
and any of the measures of clinical improvement. It is widely assumed 
that the mode of action of tricyclic antidepressants is directly related 
to the inhibition of the reuptake of released amines. It might therefore 
have been predicted not only that there would be a relationship between 
5-HT uptake inhibition and clinical improvement, but also that zimelidine 
would be a more effective treatment than amitriptyline. This finding of
Table k.2
Clinical progress of patients receiving either amitriptyline
or zimelidine 
Hamilton rating scores shown as mean _+ S.E.M.
Stage of trial Amitriptyline Zimelidine
n = 15 n = 15
Baseline pre-entry 20.8 _+ 0.9 39*7 +. 0.8
2 weeks “ lU.9 + 0.8 lU.8 + 1 .U
■ k weeks lU.l + 3.5 12.7 + 1.9
6 weeks *12.7+1.9 12.2+2.3
Ta
bl
e 
k
.3 
•
Up
ta
ke
 
of 
5“
HT 
by 
pl
at
el
et
s 
fr
om
 
de
pr
es
se
d 
pa
ti
en
ts
 
an
d 
fr
om
 
pa
ti
en
ts
 
re
ce
iv
in
g
ei
th
er
 
am
it
ri
pt
yl
in
e 
or 
zi
me
li
di
ne
 
Re
su
lt
s 
sh
ow
n 
as 
me
an
 
+ 
S.
E.
M.
d
•H
rH
ft
l>i CO.o
H
I
ft
y 00 
n o
rHO
&ft
W  PL
&o
+ 1 +1 
*
° CO
CO CO
Lf\O
O 
+ 1
os
OJ
-4-t-
o 
+ 1
*
CO
vo
cvj
OJ
0
d to
•H p
H 0
0 0
W
a3
P
0 0
d d
•H •H
rH rH
S
P •Pft ft
•H •H
d d
-P ■P
•H •H
I 4
o
OJ 
+1
o\
LTV
o
o 
+ 1
vo
vo
CO
o
+1
|Cc
OS
irv
Lf\ vo
VO 0 . .. . COT-i CO
+ 1 + 1
+ 1 + 1
OO OJ 0 c-. . • •
OS vo C“ C—T—t OJ OJ OJ
c— 
o 
+1
**
00
vo
co
' a)
.5
rH
0cod
P
0
d
•Hnd
•H
rH
0
a
•H
CO
w
p
0
0
£
0
d
•rH
•H
r*H<U
.a
IS]
oo
o
V
ft
OJo
o
V
ft
03
d
0
•H
■y
ft
fd
0
0d
-P
d
•H
d
0
J*o
rH
I J>> 
*d
d
0
P
bO
• H
P
wa
LTvO
ft
■d
0
cJ
0
d
-P
0
d
•H
H>>
-P
ft
•Hd
-p•H
p+3
d
0
P
bu
•H
P
+-
a complete lack of correlation between inhibition of 5-HT uptake and 
clinical outcome casts doubt on the amine hypothesis of depressive illness.
Ci’C). Plasma drug concentrat'Cons and platelet 5-HT uptake
Plasma drug concentrations reached steady-state levels during the 
second week of treatment. At 4 weeks the mean plasma concentrations of 
amitriptyline (378 29 nM) and nortriptyline (393 + 49 nM) were similar.
Plasma drug levels in patients receiving zimelidine were higher than those 
in patients receiving amitriptyline, probably due to the larger dose.
Also, the plasma concentrations of the metabolite norzimelidine were 
higher (868 + 34 than those of zimelidine (524 + 97 nM). There
were no significant correlations between plasma drug levels (amitriptyline, 
■nortriptyline, amitriptyline •+ nortriptyline; zimelidine, norzimelidine, 
zimelidine + norzimelidine) and the therapeutic effect, whether assessed 
as raw Hamilton rating score, amelioration score, or percentage improvement 
in either of the•two treatment groups.
The binding of zimelidine and norzimelidine to plasma proteins 
was measured by equilibrium dialysis in plasma samples from 9 patients who 
had received zimelidine for 4 weeks. It was found that zimelidine bound 
to plasma proteins to a greater extent C8.4 2. 1.1% free) than did its 
metabolite norzimelidine (20.7 +1*0 % free). Since the plasma drug 
concentration and the percent free portion are both higher for norzimelidine 
then plasma free norzimelidine is much higher than plasma free zimelidine.
The extent to which zimelidine and norzimelidine bind to plasma
proteins was measured in plasma samples from 20 normal controls. All the
3subjects were completely drug-free: the H-labelled zimelidine or 
norzimelidine used for the estimation was the only drug present, so that 
the total drug levels in these samples was very low compared with the 
levels in the patients' samples. Very similar results were obtained for 
the control subjects: zimelidine was only 9.7 + 0.6% free, and norzimeli­
dine was 21;.4.+'0.5% free. Thus the extent to which zimelidine and 
norzimelidine bind to plasma proteins is remarkably constant.
Since there is very little variation between individuals in the 
extent to which zimelidine and norzimelidine bind to plasma proteins, the 
percentage free drug values did not correlate with total drug concentrations
Using the percent free and total drug concentrations, the concentrations 
of free zimelidine and free norzimelidine were calculated for the patients. 
Plasma free zimelidine concentration correlated significantly with total 
zimelidine plasma concentration (r = 0.85; p < 0.01); free norzimelidine 
correlated significantly with total plasma norzimelidine concentration 
(r = 0.95; p <0.001). There were no significant correlations between 
either free zimelidine or free norzimelidine and therapeutic outcome, 
although there was a trend towards a positive correlation between free 
norzimelidine and clinical improvement (Tree norzimelidine and Hamilton 
rating score at 4 weeks, r = 0.53). Thus too high a plasma drug level 
may be associated with a poor clinical response.
In the patients who received amitriptyline there were significant
correlation between plasma drug levels and.the inhibition of platelet
5-HT uptake. The 4 week value of K ,■ the increase in K from the baseline 
r nr m
value, and the percentage increase In IT all correlated significantly 
with the plasma concentration of amitriptyline at 4 weeks (Table 4.4).
These measures also correlated significantly with the total plasma level 
of amitriptyline plus nortriptyline, but not with the plasma levels of 
nortriptyline. Partial correlation confirmed that it is amitriptyline 
rather than Its metabolite nortriptyline which inhibits platelet 5-HT 
uptake.
Similar effects on platelet 5-HT uptake were observed when 
amitriptyline and nortriptyline were added in vitro (Table 4.5). 
Amitriptyline acted as a competitive inhibitor, causing an increase in Km>
but having no effect on M ' . The extent of the increase in K was not so• max - m
great in vitro as In vivo, and this is probably due to the fact’ that the 
concentration of amitriptyline added to the PRP in vitro (100 ng/ml) was 
lower than the concentration of amitriptyline found in vivo (119 + 9 ng/ml, 
range 67 to 197 ng/ml). However, the effect of amitriptyline in vitro on 
5-HT uptake by platelets from control subjects differs from its effect on 
platelets from depressed patients in that there Is a reduction in Vjnax as 
well as an increase in K^ . Thus in samples of PRP from controls amitrip­
tyline acts as a mixed Inhibitor. This difference may be simply explained 
by the fact that the drug-free value of Vmax was higher in the control 
subjects than in the the depressed patients, while the values of Vmax 
obtained for the two groups after the addition of amitriptyline to the PRP 
in vitro were very similar. Conversely, it may be that there is some other 
difference between the samples of PRP from controls and those from depressed 
patients which causes the amitriptyline to behave differently in the
Table
Product - moment correlation coefficients between 5“HT uptake 
characteristics of patients on amitriptyline and plasma
drug concentrations
Amitriptyline Nortriptyline Ami + Nor
 ^week K m
*
+0.67 +0.53
*
+0.67
A K m
**
+0.77 . +0.53
*
+0.69
% change K m
**
+0.80 +0.58
*
+0.7^
h week Vmax +0.10 +0.39 +0.32
A V max +0.U1 +0.23 +0.33
% change V
max +0.56 +0.33 +0.U7
 ^week y -0.U3 -0.15 -0.30
A y +0.0U -0.30 -0.19
% change y -0.20 -0.36 -0.3^
n = 11 for 1* week values 
n = 10 for A and % change values
p < 0.055 p < 0.01
(1) . . .Paz'tial correlation between A K and amitriptyline
. (2) . . .  mconcentration , elimiatmg effect of nortriptyline
(oy •
concentration r^  ^  = +0.67 p < 0.05
Partial correlation between A K ^  and nortriptyline
C3) . . .  111 . .concentration , eliminating effect of amitriptyline
(2 )
concentration' r ^  2 = no  ^significant
• 
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different samples. The effect of nortriptyline in vitro on the uptake of 
5-HT by platelets from control subjects was very similar to the effect 
of amitriptyline: was increased and m^ax was reduced.
Correlations between changes and plasma drug levels were also 
found in patients receiving zimelidine, but in this group the only 
correlation which reached significance was that between norzimelidine 
concentration and the percentage change in y from baseline to 4 weeks 
(Table 4.6). The correlations between free drug plasma levels and 
platelet 5-HT uptake characteristics were gYeater than those obtained 
using total drug concentrations, though few reached significance (Table 4.7). 
The difference between the total and the free concentrations of zimelidine 
and norzimelidine with respect to their relationship to platelet 5-HT 
uptake would suggest that it is the non-bound portion of the drug that is 
biologically active. Also norzimelidine appears to have a greater effect 
than zimelidine, though this may Be due to the fact that free norzimeli­
dine levels are higher than free zimelidine levels.
Zimelidine added in vitrc had a similar effect on platelets from
depressed patients and control subjects: it caused a decrease in the total
uptake of 5-HT, as indicated By the lowered value of y, By causing a
decrease in V (Table 4.8). There was no change in the value of K , max ° m
therefore zimelidine in vitro acts as a'non-competitive inhibitor of
platelet 5-HT uptake. This is in contrast to the results which were
observed in vivo, where uptake of 5-HT was reduced By a large increase
in K and no effect on V (Table 4.2). The concentration of zimelidine m max J
used for the experiments in vitro (200 ng/ml) was fairly close to the 
observed plasma concentration of zimelidine after 4 weeks of treatment with 
the drug (214 + 39 ng/ml). There are several possible explanations for 
this discrepancy in the results. One is that the pre-incubation time of 
5 minutes, the interval between the addition of zimelidine to the PRP 
-and the addition of the -^ C - labelled 5-HT, might have been too short to 
allow the zimelidine to bind to plasma proteins to the same extent as 
in vivo. This is unlikely as the same time interval has been used 
satisfactorily for other compounds. A more likely explanation is that 
the effect observed in vivo- was due to the action of a metabolite of 
zimelidine rather than that of the parent compound. The observed 
correlation between platelet 5-HT uptake and free zimelidine concentrations 
might be explained by a linear relationship between the level of zimelidine
Table k .6
Product - moment correlation coefficients between 5“HT uptake 
characteristics of patients on zimelidine and plasma 
drug concentrations
Zimelidine Norzimelidine Zim + Norzim
k week K m
V.
'+0.3V ' +0.51 +0.2*1*
A K m +0.31 +0.^7 +0. Uo
% change +0.13 +0.2^ +0.22
U week Vmax -0.03 +0.22 +0.09
'
A Y max +0.07 -0.-11 -0.01
% change Vmax +0.01 -o. iU -0.06
... -
week y -0.33 -0.06 -0.21
i y +0.07 -Q.lH -O.I6
% change y -0.32 -0.58* -0.1*7
n = 15 for k week values 
n = 13 for A. and % change values 
* p < 0.05
Table ^. 7
Product - moment correlation coefficients between 
5-HT uptake characteristics of patients on 
zimelidine and plasma free drug concentrations
— Free zimelidine Free norzimelidine
h week K m ' ’ +0 .'30 +0.68
A K 
m
% change K m
+0.52
*
+0.72
+0.69
+0.52
k week Vmax -0.12 +0.^8 \
A V max +0.07 -0.36
% change Vmsix -0.23 -0.59
U week y -0.62 -0.15
A y -0.32
*
-0.76
% change y . -0.62 -0.87
n = 9 for U week values
n = 8 for A and % change values
*
P < 0.05
p < 0.01
Table k.8
Effect of zimelidine (200 ng/ml PRP) and norzimelidine (200 ng/ml PRP) 
in vitro on the uptake of 5-HT by platelets from control 
subjects and depressed patients.
Results shown as mean + S.E.M.
Group n Km
V
Vmax y
(]1M)
8(pmol/30 platelets/min)
Depressed patients 7 0.76 + 0.16 3^.7 ±  5.2 39.3 ± *^9
Patients + zimelidine 7 0.75
V
+ 0.15 3 8.2* + J..U
**
30.5 ± 0.9
Control subjects 7 0.^5 + 0.05 32. It + 8.0 39.6 " + 5.3
Controls and zime'lidine 7 0.60 + 0.08 23.2* + 5.k
***
33-3 ± 3.7
Control subjects 5 0.36* *
00
38.9 ±9.1 23.7 + 6.5
Controls and norzimelidine 5 4.68 + 0.63
*
26.0 ±'h.-k 5.9 ±3.7
Significant.differences by paired tests
* ** ***
• p < 0.05, p < 0.02, p < Q.Q3
and the concentration of its more active metabolite. This hypothesis is 
supported by the results of the experiments in which norzimelidine, the 
primary metabolite of zimelidine, was added in vitro to samples of PRP 
from control subjects (Table 4.6).
Norzimelidine caused a large increase in the value of K , and am
proportionately smaller, but still significant, decrease in ^max> These 
results are similar to those found for the effect of anitriptyline in 
vitro on platelets from control subjects (Table 4.5). The concentration 
of norzimelidine used for the experiments in vitro (200 ng/ml) was much 
lower than the plasma concentrations found in patients receiving zimelidine 
for 4 weeks (342 > 33 ng/ml). Since the plasma concentration of 
norzimelidine at steady state conditions (342 ng/ml) was almost twice 
as great as that of zimelidine (214 ng/ml) it is possible that the 
metabolite exerts a greater effect than the parent compound. If the 
assumption that it is only the non-protein-bound portion of the drug that 
is biologically active is valid, then the descreparicy is increased, since . 
zimelidine binds to plasma proteins to. a greater extent (only 8.4 +_ 1.1% 
free^ than does norzimelidine (20.7 1.0% free). The plasma concentration
of free zimelidine was only 38.6 + 7.1 ng/ml, while the plasma concentration 
of free norzimelidine was 189.3 +; 24.3 ng/ml.
Ciiil Platelet tryptophan uptake and plasma levels of tryptophan ^ 
phenylalanine and tyrosine.
Tryptophan uptake characteristics were determined for platelet 
samples from 20 depressed patients at baseline, and; after 4 weeks of 
treatment, from 8.patients receiving amitriptyline and from 10 patients 
receiving zimelidine. Neither amitriptyline nor zimelidine had any 
significant effect on platelet tryptophan uptake (Table 4.9).
  Plasma percentage free tryptophan was determined by the equilibrium
dialysis method for 5 patients before and during treatment with 
amitriptyline and for 9. patients before and during treatment with 
zimelidine. Neither treatment had any significant effect on percentage 
free tryptophan or free tryptophan concentration (Table 4.10). Both 
treatments caused a reduction in plasma total tryptophan concentration, 
though this only reached significance in the amitriptyline group.
Plasma concentrations of tryptophan, tyrosine and phenylalanine
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Table 1.10a
Total, percent free and calculated free plasma tryptophan 
in 5 depressed patients before and during 
treatment with amitriptyline 
. Results shown as mean + S.E.M. -
Baseline On amitriptyline
Total tryptophan (pM) 52.1 + 3.6 13.6* +2.9
% free tryptophan 23.3 + 0.2 26.5 + 2.9
• - .
Free tryptophan &iM) .12.3 ± 0.3 33.3 + 0.8
p < 0.05 (method of paired comparisons). •••
Table 1.30b
Total, percent free and calculated free plasma tryptophan 
in 9 depressed patients before and during 
treatment with zimelidine 
Results shown as mean _+ S.E.M.
Baseline On zimelidine
Total tryptophan QjM). 53.0 + 2.1 18.5+2.3
% free tryptophan 26.3 + 2.6 25.8 +3.1
Free tryptophan (pM) 33.6 + 3.3 32.8 +_ u. 5
Table ^.I1a
Plasma tryptophan, tyrosine and phenylalanine 
concentrations in 17 depressed patients before and during 
treatment with amitriptyline 
Results shown as mean + S.E.M.
Baseline On amitriptyline
Tryptophan (yM) 5I+.O + 2.1 50.5 + 2.2
Tyrosine (yM) 76.6 + 3.1 79.6 + h.3
Phenylalanine (yM) • 67.7 + 2.9 63.6 .^5 -
Table U.11b
. Plasma tryptophan, tyrosine and phenylalanine 
concentrations in 13 depressed patients before and during 
treatment with zimelidine 
Results shown as mean + S.E.M.
Baseline On zimelidine
Tryptophan CyM) 
Tyrosine (yM) 
Phenylalanine (yM)
+ 2.6 
7*5.3 + 3.3 
68.8 + 3.8
U7.U* + 2.9 
77.  ^ ± 3.9 
70.1 + ^.3
* p < 0.05 (method of paired comparisons)
Were measured in samples from 17 patients before and during treatment 
with amitriptyline, and from 13 patients before and during treatment 
with zimelidine. Both treatments caused a reduction in tryptophan 
concentration, though this only reached significance in the zimelidine 
group (Table 4.11). Neither treatment caused any significant change in 
the plasma concentration of tyrosine or phenylalanine.
(D) SUMMARY •
In this trial the clinical effectiveness of zimelidine was 
shown to be of the same order as amitriptyline in thie treatment of 
primary depressive Illness. The Incidence of unwanted subjective side- 
effects was found to be less, and probably reflects the weak anticholin- 
.ergic activity of zimelidine. After 6 weeks of treatment with zimelidine 
the corrected side-effects score was negative, and since many of the side- 
effects are a reflection of depressive state, the decrease in the side- 
effects score reflects the clinical Improvement of the patients. As is 
generally found with antidepressant drugs, there were no significant corr­
elations between plasma drug concentrations and therapeutic effect.
Both amitriptyline and zimelidine in clinically effective doses 
caused highly significant inhibition of platelet 5-HT uptake. The lack 
of any correlation Between the Inhibition of 5-HT uptake caused by these 
drugs with clinical improvement casts doubt on their supposed mode of 
action. -
THE EFFECTS OF MIANSERIN AND LITHIUM ON PLATELET 5-HT UPTAKE IN RECOVERED 
DEPRESSIVE PATIENTS.
(A) MIANSERIN .
Mianserin hydrochloride has a tetracyclic piperazinoazepine 
-“Structure and has been shown in controlled trials to have an antidepressant 
effect. Although classical animal pharmacological tests failed to predict 
any antidepressant activity for this compound, it was found that mianserin 
produces changes in the human electroencephalogram similar to those 
produced by the tricyclic antidepressants (Itil, 1973). The effects of 
mainserin have been compared with those of tricyclic antidepressant 
drugs, and It has been shown to have an antidepressant effect comparable 
with amitriptyline (Wheatley, 1975) and imipramine (Murphy, 1975), and to
be superior to placebo (Murphy, Donald and Moller, 1976). It has also 
been found that, compared with most tricylcic antidepressant drugs, 
mianserin produces fewer and less severe unwanted side-effects as it 
has less anticholinergic activity (Murphy, 1975; Coppen et al., 1976).
The plasma half-life of mianserin Is 6 to 12 hours. Stable 
steady state levels are reached after 2 weeks administration (Coppen 
and Ghose, 1976). The drug Is 90% to 95% protein bound in the plasma 
at therapeutic concentrations QCopera, 1975). Animal experiments have 
shown that mianserin rapidly enters the brain and becomes evenly 
: distributed in the central nervous system.
Tt has 'been reported that,•In .contrast to tricylcic antidepressant 
.drugs, mianserin in therapeutic concentrations in vivo does not block 
the central noradrenaline reuptake mechanisms in rats (Leonard, 1974). 
However, Raiteri, Angelini and Bertollini (1976) found that in vitro 
mianserin behaved similarly to imipramine in blocking noradrenaline uptake 
in rat hypothalamic synaptomomes. This group also investigated the effect 
of mainserin on rat blood platelet uptake of 5-HT, using incubation times 
.of 10 minutes, and were unable to detect any inhibition of 5-HT uptake 
with mianserin at a concentration of 2 x 1(T^ M.
Mianserin Is of Interest since it is the first antidepressant drug 
to apparently Increase noradrenaline release by an effect on the presynaptic 
«2 - receptors (Raumann and Maitre, 1975). It is only slightly active- 
as an Inhibitor of the uptake of 5-HT and noradrenaline, and it has been 
shown to be a 5-HT receptor antagonist (Saxena, Van^Houwelingen and 
Bonta, 1971).
A description of the medical use of lithium salts Is given at the 
beginning of Chapter 5.
(BI PATIENTS -
A trial was conducted to compare the effectiveness of lithium 
carbonate and of mianserin hydrochloride as prophylactic medication for 
the prevention of recurrence of depression.
A group of 3 male and 15 female patients was studied. These
patients had all been admitted to hospital suffering from primary, 
depressive illness, and had been treated with either antidepressant 
drugs (amitriptyline, cyclaziridole or zimelidine) or ECT. The medication 
was withdrawn in those patients who had recovered, and after a further 
14 days without antIdepressant drug treatment their clinical state was 
assessed. Those patients with a Hamilton rating score of 6 or less were 
regarded as recovered, and were included in the study.
At the end of the drug-free period, a baseline blood sample was 
collected, after overnight fasting, for the-estimation of platelet 5-HT 
and tryptophan uptake, and plasma concentrations of tryptophan, tyrosine 
and phenylalanine. The patients were then randomly allocated to receive 
either lithium carbonate or mianserin hydrochloride. For those patients 
’who received lithium the dose was adjusted to produce a plasma concentra­
tion of about 1 mM, measured approximately 13 hours after the previous 
evening's dose. The patients on mianserin received 20 mg three times 
daily, I.e. 60 m‘g per day. The patients were treated on an out-patient 
basis during the course of the study. The treatment was continued for 
6 weeks, after which time the patients returned to the out-patient 
clinic for a further blood sample to be taken for the estimation of plasma 
drug concentration, and for a repeat of the platelet 5-HT and tryptophan 
uptake measurements and determination of plasma concentrations of 
tryptophan, tyrosine and phenylalanine.
(Cl RESULTS
C£l. Platelet 5-ET uptake and plasma drug concentrations
Mianserin and lithium both caused an increase in platelet 5-HT 
uptake (Table 4.12] (The results obtained for the patients who received 
lithium are also presented In Chapter 5.). Both treatments caused a
 small increase in K^ , though this only reached significance in the mianserin
group. Both treatments caused a significant increase in both and y.
Lithium had a greater effect on the rate of 5-HT uptake than did mianserin. 
Patients receiving lithium had a significantly higher value of y than did 
patients receiving mianserin. Thus, in contrast to antidepressant drugs 
such as amitriptyline and zimelidine, which inhibit platelet 5-HT uptake, 
both lithium and mianserin increase platelet 5-HT uptake in depressive 
patients towards normal control values.
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. The plasma mianserin concentration at 6 weeks was available for 
7 patients. The mean was 39.1 + 4.7 ng/ml. The plasma lithium concentra­
tion was available for 7 patients and the mean was 0.93 + 0.05 mM (the 
eighth patient forgot to take her tablets on the evening prior to the 6 
week appointment and had a plasma lithium level of only 0.06mM).
There were no significant correlations between plasma drug concentration 
and platelet 5-HT uptake characteristics, or change in platelet 5-HT uptake 
from baseline, in either the mianserin or the lithium group.
Mianserin hydrochloride at a concentration of 50 ng/ml was added
in vitro to platelet samples from 3 recovered depressive patients and 7
control subjects. In the samples from patients mianserin caused an
increase in K and a small decrease in V : these changes were not m max
• significant, probably due to the small sample size. In the samples from
control subjects mianserin had no effect on r, but caused a significant
decrease in V (Table 4.13). It is possible that mianserin has a max .
different.effect on platelets from depressive patients than on platelets 
from control subjects, though for both groups the effects observed in vitro 
were different from the effects observed in vivo in depressive patients.
An analogue of mianserin, GC94, and two metabolites of mianserin, 
GF45 and OH46, were added in vitro to platelet samples from control 
subjects. The concentration used in each case was 50 ng/ml. None of !
these compounds had any effect of K^ , and all caused a significant reduc­
tion in Vmax (Table 4.14). These results fail to throw any light on the 
observed effects of mianserin in depressive patients.
t'i'i) ’Platelet tryptophan uptake and plasma concentrations of tryptophan,3 
phenylalan-ine and tyrosine. ~ ’
Platelet tryptophan uptake was measured in samples from 11 
-— recovered depressive patients, 9 patients receiving mianserin and 8
patients receiving lithium. There were no significant differences between 
the groups, although the patients on lithium had a higher platelet 
tryptophan uptake than the drug-free patients and the patients on 
mianserin (Table 4.15).
Percentage free plasma tryptophan was determined by the equilibrium 
dialysis method in plasma samples from 19 recovered depressive patients,
Table U-.13
Effect of mianserin (50 ng/ml) in vitro on 5-HT uptake by platelets 
from recovered depressive patients and control subjects 
Results shown as mean + S.E.M.
Group n Km Vmax
■' -
CpM) (pmol/10 pl/min)
Recovered depressives 3 0.1*7 ± 0.08 10.5 ± 3.6
Recovered depressives + mianserin 3 0.71 ±0.19 ;\9.3 + 1.7
Control subjects 7 0.65 ± 0.09 21.3 ± 3.6
Control subjects * mianserin ■7. 0.68 + 0.09 16.7* ± 2.9
lower than drug-free value (paired t-test, p < 0.01)
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9 patients on mianserin and 7 patients on lithium. There were no 
significant differences between the groups in percentage free tryptophan, 
total tryptophan concentration or calculated free tryptophan concentration 
(Table 4.16).
Plasma concentrations of tryptophan, tyrosine and phenylalanine 
were measured in samples from 27 recovered depressives, 10 patients 
on mianserin and 9 patients on lithium. There were no significant 
differences between the groups ( T a b l e  4.17).
■ (D) SUMMARY
Mianserin and lithium are both effective as prophylactic 
treatment for the prevention of recurrence of depressive illness, and 
both have fewer unwanted side-effects of the types caused by the 
anticholinergic activity of tricyclic antidepressant drugs. It is 
possible that both mianserin and lithium exert their prophylactic effect 
in depressive patients by increasing the rate of uptake of 5-HT towards 
normal values.
CHAPTER FIVE
THE EFFECTS OF PROPHYLACTIC TREATMENT WITH LITHIUM ON PLATELET 5-HT 
UPTAKE IN DEPRESSIVE PATIENTS
(A) INTRODUCTION : THE USE OF LITHIUM SALTS IN MEDICINE
Lithium salts were introduced into medicine in the 1550's for 
the treatment of gout, following the demonstration that lithium urate 
was the most soluble of the urates (Garrod, 1859}. The anti-manic 
properties of lithium were first described by Cade (1949). Subsequently 
a number of clinical trials demonstrated that lithium is an effective 
treatment for mania, and a powerful prophylactic against depressive 
swings in both bipolar and unipolar affective disorder (Schou et al., 
1954;Maggs, 1963; Baastrup et al., 1970; Coppen et al., 1971; Hullin, 
McDonald and Allsop, 1972). Lithium has also been used with varying 
degrees of sucess in other psychiatric disorders, including schizophrenia, 
aggression, premenstrual tension and alcoholism (Schou, 1978). Originally 
lithium citrate was the preferred salt because C'f its solubility, but 
now the carbonate is preferred as It produces less alimentary 
disturbance.
At present, the mechanism by which lithium produces Its 
therapeutic effects are unknown/ although it has been shorn that under 
some conditions of administration lithium produces alterations In the 
turnover and metabolism of biogenic amines (Knapp and Mandell, 1973; 
Collard, 1978). Haskovec and Rysanek (1969) found that lithium caused 
an increase in the excretion of 3-methoxy-4-hydroxymandelic acid 
(vanillylmandelic acid, or VMA, a metabolite of noradrenaline) in 10 
healthy control subjects. Schildkraut (1974) reported an increase 
during lithium therapy of the excretion of 3-methoxy-4-hydroxyphenyl 
glycol (MHPG, a metabolite of noradrenaline largely derived from the 
brain). In rats given lithium for 3 days the turnover of 5-HT was 
increased (Perez-Cruet et al., 1971), but after about 20 days of lithium 
administration there was a decrease in 5-HT turnover (Corrodi and Schou, 
1969). It has been suggested (Mandell and Knapp, 1977) that lithium 
first causes an increase in 5-HT turnover by increasing the high 
affinity uptake system for tryptophan into the nerve endings. In 
time a new steady - state in reached, with increased tryptophan uptake
but decreased tryptophan hydroxylase activity and reduced 5-HT 
turnover.
Several investigators have studied the effect of lithium on 
platelet 5-HT uptake. Genefke (1972) found that in rats treated with 
lithium chloride platelet 5-HT uptake was not affected, but when added 
to the incubation medium lithium chloride inhibited 5-HT uptake by 
both rat and human platelets. Murphy and co-workers (1969, 1970) 
found that treatment with lithium carbonate caused a significant . 
increase in platelet 5-HT uptake in a group of 10 patients with affective 
illness, whereas the addition of lithium chloride to the incubation 
medium had no effect on platelet 5-HT uptake. A similar finding was 
reported by Born, Grignani and Martin (1980). Coppen and co-workers . 
(1976) reported that whole blood 5-HT concentrations were low in 
depressive patients, and that lithium therapy significantly increased 
the levels of whole blood 5-HT.
(B) THE EFFECT OF LITHIUM ON PLATELET 5-HT UPTAKE IN DEPRESSIVE 
PATIENTS
For the purpose of this thesis, the effect of lithium therapy 
in patients with affective disorder was investigated in two studies.
Ci) Studies involving patients tested before and during
lithium therapy ; -
Pirst, a small group of patients who had all recently recovered 
from an episode of depression were tested both before and during 
treatment with lithium carbonate. The patients studied were admitted 
to hospital suffering from primary depressive illness and had no 
history of mania or significant physical illness. After a drug-free 
period of at least 7 days, the patients were assessed for the 
severity of their symptoms by the Hamilton Rating Scale (HRS) for 
depression, and those patients who scored 16 or more on the first 16 
items of the HRS were than treated for 6 weeks with a tricyclic 
antidepressant drug. The medication was then withdrawn in patients 
who had recovered, and after a further 14 days without drug treatment 
their clinical state was assessed. Those patients with a HRS score 
- 6 were regarded as recovered.
Blood samples for estimation of platelet 5-HT uptake characteristics 
were collected from one male and seven female recovered patients. They 
were then treated with lithium carbonate (sustained - release tablets, 
Priadel), the dose being adjusted so that a plasma level of 0.8 to 
1.0 mmol/1, measured approximately 12 hours after the last dose, was 
achieved. After six weeks' treatment a repeat blood sample was taken 
for platelet 5-HT uptake estimation.
The administration of lithium carbonate for 6 weeks caused a 
significant increase in the value (Table 5.1), but had no
effect on Kffi, or on the number of platelets in the plasma. The mean 
plasma lithium concentration was 0.82 +_ 0.12 mequiv /I.
A similar group of seven female recovered patients (including 
4 subjects from the group described above) were investigated before 
and after one year of lithium therapy. Administration of lithium 
caused a significant increase in Vma;x (Table 5.2), but had no effect 
on K^ . The number of platelets in the circulation was also increased.
The mean plasma lithium concentration was 0.90 +_ 0.04 mequfv/1.
(ii) Study of patients on long-teimi lithium therapy
Second, a group of 65 out - patients who attended the lithium 
clinic at Greenbank Ward, West Park Hospital, were tested on one or 
more occasions. At the time of testing all patients Were being 
treated only with lithium carbonate : patients receiving any other 
form of medication in addition to lithium were excluded at this stage 
of the study. The patients had been receiving lithium for from 
6 weeks to over 10 years. The group consisted of 3C female and 
16 male unipolar patients, all of whom had suffered at least 3 episodes 
of depression without any history of mania; and 10 female and 9 male 
-bipolar patients, all of whom had suffered at least one episode of 
mania, and many of whom had also had several episodes of depression.
The sex ratios in the two diagnostic categories are similar to those 
usually found, and support the hypothesis that unipolar and bipolar 
illness are genetically distinct (Leonhard, Korff and Schulz, 1962).
There were no significant differences between the sexes in
either unipolar or bipolar patients for platelet concentration,
or V (Table 5.3), so the results for males and females were combined, max J ’
There were no significant differences between unipolar and bipolar
Table 5.1
Uptale of 5~HT by platelets from 8 recovered depressive 
patients before and after 6 weeks lithium therapy 
Results shown as mean + S.E.M.
Drug-free On lithium
Platelet concentration
(x 108/ml PRP) 3.21 + 0.29 3.23 + 0.42
K (yM) m - 0.73 ± 0.10 0.7 6 t 0*J9
- Vmax * •
34.4*(pmol/108 pl/min) 22.4 + 3.4 + 4.6
-
p < 0.05, (method of paired comparisons)
Table 5.2
Uptake of 5~HT by platelets from 7 recovered depressive 
patients before and after one year’s lithium therapy 
Results shown as mean + S.E.M.
Drug-free On lithium
Platelet concentration 
(x 108/ml PRP) 2.91 ± 0.31 1 *3.7^ + 0.62
Km
CpM) 0.62 + 0.09 0.61 ± °*°5
V ; max g
(pmol/10 pl/min} • lk.1 ± 2.3 «  s** 28.6 + 3.8 ... .  -
*
p < 0.05
p < 0.01
(method of paired comparisons)
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patients, although V was slightly higher in bipolar (mean 44.7max
+^3.5 pmol/10 platelets/min) than in unipolar patients (mean 37.8 
+ 2.4).
The results for unipolar and bipolar patients were combined, 
and compared with those obtained for control subjects (as described 
in Chapter 2, but eliminating persons aged 35 years or less), 
depressed patients and recovered depressive patients (Table 5.4). 
There was no significant difference between any of the patient 
groups in age, platelet concentration or K^ . The control subjects 
were younger than the patients on lithium (p < 0.05), and also had a 
lower platelet concentration (2.64 +_ 0.10 x 10 /ml PRP) than the 
lithium patients (3.26 +_ 0.11) (d = 4.168, p < 0.001).
There was no significant correlation between platelet
concentration and age, K or V in any of the groups. There was& m max r
a significant correlation between age and V (r ~ -0.451, p < 0.01) 
in the recovered depressive patients,; In the unipolar patients 
receiving lithium there was a significant correlation between plasma 
lithium^concentration and Km (r = +0.356, p < 0.05).
The effect on platelet 5-HT uptake of adding lithium carbonate 
in vitro was examined in PRP samples from 7 control sibjects. The 
addition of lithium carbonate to a final concentration in the PRP of 
1 mequiv/1 caused a significant reduction in the rate of 5-HT uptake' 
(Table 5.5). This finding is in agreement with the report by 
Genefke (1972) that lithium chloride inhibited 5-HT uptake when added 
to the incubation medium.
Although all subjects were asked to fast overnight prior to 
venepuncture, it is possible that some of the lithium clinic out­
patients may have neglected to do so. In order to confirm that, as 
found with control subjects (see Chapter 2), the consumption of 
"breakfast" has no effect on the platelet 5-HT uptake results, a 
group of 14 patients (9 female unipolar, 3 male unipolar, one female 
bipolar and one male bipolar), all of whom were known to be reliable, 
were tested once when fasting, and then again when not fasting at 
their subsequent visit to the clinic. The test - re-test interval
Ta
bl
e 
5.
 ^
Pl
at
el
et
 
5-
HT
 
up
ta
ke
 
ch
ar
ac
te
ri
st
ic
s 
of 
co
nt
ro
l 
su
bj
ec
ts
, 
de
pr
es
se
d 
pa
ti
en
ts
, 
re
co
ve
re
d 
de
pr
es
si
ve
s,
 
an
d 
de
pr
es
si
ye
 
pa
ti
en
ts
 
re
ce
iv
in
g 
li
th
iu
m 
th
er
ap
y 
Re
su
lt
s 
sh
ow
n 
as 
me
an
 
+ 
S.
E.
M.
d•H -=f -=r CM o* » • •
CM T-| CM CM
3
i—1
ft +1 + 1 + | + |
a CO *
> O * *T~t * *
tr\ CM CM CO
1—1 . . . • ' •o OS CO -=f ov
i .  . CO CO CM 00pi*
CM CO CO co
O o O o• • • •
o a o o
LJR s +1 +1 + 1 + i ' :■. ft o ' CM -=r LTNLPi Lf\ LT\ U"\• • • •
o O o o
CM VO -=f -M- '. . • •r-i T-I CM TT
. o + 1 + i + 1 Hr I*W) u
<5 >> *O CO CM T-T. . • •
*~l T~> CM LTNirv ITS LTN IP.
co c— CO IP. '
d p" CO VO
0
0
' > g
0 •H p
p 0 •H
CO d 0 ,d
P 0 0 p
o •H ' d •H
ft 0 P ft H
d •o cJ 0o £ ft fd d
d d oo CO fd •d
0 0 0
rH 0 d p
O 0 0 d
d 0 > 0
P M o •r!
d ft o Po 0 ,0 do P ft ft
• H
,d
-p
H
#>
L T \ LTN
O O• •
o o
V V
ft ft
r> r>
0 0H HO O
d d
P  ■ P
d do Oa o
d c
d d
,d ,d
p -P
d d0 0
'd >H O
O rH
oo
ft
0
O P
• d
o . 0
•H
Y
ft ft
n ^
0 d
p • H
d >d
d p
•H •H
P H
d
ft >d
0p
d<u•H
Pi
'd
0
0
0<u
dPi
0fd
co
i— Iod
C3oO
§,d
P
d
0
o
rH
Table 5 .5
Effect on platelet 5~HT uptake of lithium carbonate 
added in vitro to PEP from 7 control subjects
Results shown as mean +_ S.E.M.
Km
(pM)
Vmax
ft(pmol/10 pl/min)
Control subjects 0.61 + 0.16 2b.8 + 5.0 
*
Controls + Li^ C0^ 0.80 + 0.32 16.3 + -^9"
-
p < 0.01 (method of paired comparisons)
Table 5.6
Platelet 5"HT uptake in lb patients on lithium tested twice:
with and without fasting 
Results shown as mean + S.E.M.
Fasting Rot fasting
Platelet concentration
o
(x 10 /ml PRP) 3.27 + 0.29 3.23 + 0.26
K ’ 'm
(pM) ' 0.Ml * 0.03 0.i+9 + 0.0U
Vmax
o ’
(pmol/10 platelets/min); 43.8 +_ 3.6 ^9-3 +_ 3.2
Plasma lithium concentration
(mequiv/L) 0.75 ± 0.03 0.71* + 0.06
was from 6 to 10 weeks, which was short enough to eliminate any 
possible effects of seasonal variation. It was found that consumption 
of MbreakfastM had no significant effect on the results (Table 5.6).
Due to participation in various studies to compare the efficacy
of lithium in conjunction with or instead of other treatments, a
number of patients on lithium only were tested on several occasions.
The results for a group of 9 patients (2 male unipolar, 4 female
unipolar, and 3 female bipolar) who had been tested on four or more
occasions were examined for intraindividual variation (Tables 5.7 and
5.8). The intraindividual variation, as indicated by the coefficients
of variance, in both K and V was similar to that found in control ’ m max
subjects (Chapter 2, Tables 2.7a and 2.7b), with a mean coefficient
of variance of about 30% for both K and V in both groups. However,m max b r -
the mean coefficient of variance of platelet concentration was lower 
(15%) in the lithium treated patients than in the controls:(25%).
In order to investigate the possible effect of seasonal 
variation, the results obtained.for platelet 5-HT uptake in patients 
receiving lithium therapy were divided into two - monthly groups, 
according to the system used for the control subjects (Chapter 2).
A total of 132 platelet 5-HT uptake results were' available.
As found in control subjects and drug-free depressive patients 
(Chapters 2 and 3), the rate of platelet 5-HT uptake in lithium - 
treated patients was greatest in the winter and lowest in the summer 
(Figure 5.1). This finding emphasises that it is essential to test 
concurrently groups of subjects which are to be compared.
\
A considerable proportion of the lithium clinic out-patients 
require hypnotics. In order to investigate the possible effects on 
-platelet 5-HT uptake of nitrazepam (Mogadon), a commonly administered 
hypnotic, a group of 21 patients who were receiving both lithium 
and nitrazepam were tested, and the results compared with those for 
a group receiving lithium only, matched to the first group as closely 
as possible for age, sex, diagnosis and month of test.
It was found, as might be expected, that it was the older 
patients who were receiving nitrazepam, the mean age of the group 
receiving both lithium and nitrazepam being 61.8 ^1.9 years. These
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Legend to Figure 5.1
Seasonal variation in platelet 5-HT uptake in depressive patients 
receiving lithium
Points shown as mean with standard error bar
V A lower than January + February, p < 0.05, and March + Aprilmax
p < 0.02
B lower than January + February and March + April p < 0.001
C lower than March +. April p <0.02 July + August p < 0.05
and September + October p < 0.001
D higher than January + February p < 0.01
Figure 5.1 Seasonal variation in platelet 5-HT uptake in 
depressive patients receiving lithium
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Table 5*9
Platelet 5“HT uptake in patients receiving lithium only, 
or lithium with nitrazepam 
Results shown as mean + S.E.M.
Lithium Lithium + Nitrazepam
Number of patients 21 21
Age (yr) 55.6 + 2.6 61.8 + 1.9
Q
Platelet cone (x 10 /ml PEP) 3.32 +0.27 3.33 + 0.21
K CpM) m 0.50 + 0.03 O.bp +0.03
8V (pmol/10 platelets/min) msix . k2.J ± b.O 28.2* + 2.7
Plasma Li cone11 (mequiv/L) 0.85 ± 0.0U 0.95 ± 0.0b
*
p < 0.01
Table 5.10
Platelet 5“HT uptake in patients receiving either lithium only,
or . lithium with valium 
Results shown as mean + S.E.M.
Lithium Lithium + Valium
Number of patients 5 5
Age
(yr) ' + 3.3 57.2 + 3.5
Platelet concentration
o
(x 10 /ml PRP) 3.Ho + 0.31 3.05 + 0.H5
K .m
(yM) 0.5H + 0.07 O.HH + 0.05
Vmax n
Cpmol/10 platelets/min) 37.2 7.8 HO.H + 6.
Plasma lithium concentration
(mequiv/L) 0.80 + .0.03 0.87 + 0.08
Table 5.11
Effect on plateletV5~HT uptake of diazepam added 
in vitro to PRP from 6 control subjects 
Results shown as mean. + S.E.M.
Km
CyM)
Ymax
Q
(pmol/10 pl/min)
Control subjects 0.1*2 + 0.03 1*2.0 + 3-0
*
Controls diazepam 0.38 + 0.02 29.5 ± 2.6
p < 0.01 (method of paired comparisons)
patients had a significantly lower rate of platelet 5-HT uptake than 
the patients on lithium only (Table 5.9). This finding is contrary 
to the widespread view that benzodiazapines have no effect on the 
transport of biogenic amines.
In order to investigate the possible effects of diazepam 
(valium), a commonly administered anxiolytic, a group of 5 patients 
who were receiving both lithium and diazepam were tested, and the 
results compared with those for a group receiving lithium only, matched 
to the diazepam group as closely as possible for age, sex, diagnosis and 
month of test. It was found that diazepam had no significant effect 
on platelet 5-HT uptake in patients receiving lithium therapy (Table 5.10).
Diazepam, final concentration 200 ng/ml, was added in vitro
to PRP samples from six control subjects. It.was found to cause a
significant reduction in V but had no effect on the K of plateletmax m i
5-HT uptake (Table 5.11).
(C) SUMMARY
In depressive patients receiving prophylactic treatment with 
lithium carbonate the rate of uptake of 5-HT by platelets was found 
to be increased to control values. This finding is in agreement with 
other reports in the literature (Murphy et al., 1970; Bom, Grignani 
and Martin, 1980; Meltzer, Arora and Goodnick, 1983), and is in accord 
with the observation that lithium therapy significantly increased the 
levels of whole blood 5-HT in depressive patients (Coppen et al., 1976).
'There was found to be a seasonal variation in the rate of 
platelet 5-HT uptake in patients receiving lithium therapy. The 
pattern of variation was similar to that found for drug-free depressive 
patients, with the rate of uptake being greatest in the winter and 
lowest in late spring and early summer.
CHAPTER SIX
*
DISCUSSION OF RESULTS
(A) PLATELET 5-HT UPTAKE IS REDUCED IN DEPRESSIVE PATIENTS
i
The rate of platelet 5-HT uptake was lower in depressive 
patients than in age and sex matched control subjects. The defect 
in the patients’ 5-HT transport system was independent of clinical 
state, as there was no correlation between severity of illness and 
rate of 5-HT uptake in depressed patients, and the results for a group 
of patients tested both when depressed and again after recovery were 
similar on the two occasions.
If the assumption that the kinetics of platelet 5-HT uptake 
are similar to the kinetics of 5-HT transport across synaptic membranes 
is valid for human tissues (the evidence for this assumption is based 
on results obtained on laboratory animals), then the results described 
here are consistent with the biogenic amine: hypothesis of depressive 
illness by supplying .evidence of a reduced availability or turnover 
of neuronal 5-HT. The reduced rate of 5-HT uptake in depressed patients 
leads to a lov. platelet 5-HT content (Coppen et^  al., 1976). A low 
rate of 5-HT transport in the brains of-depressed patients may be
related to the reduced 5-HT concentrations observed in the brains of
people who have committed suicide (Shaw, 1966; Bourne et al., 1968;
Lloyd et_ al., 1974).
Since the impairment of platelet 5-HT In depressive patients 
is apparently unrelated to clinical state, it is suggested that a low
rate of 5-HT uptake is a trait contributing to a predisposition to
depressive illness. Although the rate of 5-HT uptake is significantly 
Tower in patients than in control subjects, there Is a great deal of 
overlap between the groups, i.e. a high rate of uptake does not 
necessarily mean that the subject is Immune to depressive illness or, 
since it is possible that some of the control subjects, although without 
a history of psychiatric illness, may suffer from depression in the 
future, a low rate of 5-HT uptake does not necessarily confirm that the 
subject is prone to depression. A reduced rate of 5-HT uptake thus 
probably contributes to, but is not essential for, vulnerability to the
affective disorders.
Taken alone, the measurement of a patient’s platelet 5-HT 
uptake characteristics will neither confirm nor disprove a diagnosis 
of depression. However, it may still be of diagnostic use if carried
i
out in conjunction with other biological assays, e.g. the dexamethasone 
suppression test.
+ '+ .
(t) Effect of membrane Na /K ATPase activity on 5-HT transport 
Platelets, like most cells, maintain a low internal sodium
2 4. ,|
concentration by means of Mg -dependent Na /K -stimulated ATPase in
+ +
the membrane, which transports Na outward and K inward against a
concentration gradient. The active uptake of 5-HT by platelets shows
an absolute dependence upon the extracellular Na+ concentration, and
in the absence of. Na+ there is no net 5-HT uptake (Lingjaerde, 1969).
There are reports of decreased Na+/K+ATPase activity in membrane
preparations from depressed patients (Choi, Taylor and Abrams, 1977;
Hesketh, Glen and Reading, 1977; Naylor et al., 1980), although there
is one report.of an increase in Na+/K+ ATPase activity in depressives
(Sengupta, Datta and Sengupta, 1981). All used erythrocyte membranes
4" 4*
rather than platelet membranes, but probably the membrane Na /K ATPase 
activity is similar in both erythrocytes and platelets.
• If the reports of decreased Na+/K+ ATPase activity in depressfed 
patients are validated, then this could account for the reduced rate 
of 5-HT uptake by platelets. This is supported by-a report of a 
correlation between platelet 5-HT uptake and platelet 5-HT content 
(Worz-Justice, Lichsteiner and Feer, 1977). One group measured not 
only the activity of the enzymes but also the number of sodium pump 
sites per erythrocyte, which was found to be similar in control subjects 
-and depressed patients (Nayior et al., 1980). This might explain the 
similar K values for 5-HT uptake in controls and depressive patients. 
If, on the other hand, Na+/K+ATPase activity is normal or increased 
in depressed patients, then the normal Km and reduced V ^  of depressive 
patients might be explained by a deficiency in the dense granules which 
store the accumulated 5-HT within the platelet. This possibility is 
supported by the lack of correlation between 5-HT uptake and 5-HT 
content in platelets from control subjects reported by Stahl, Ciaranello 
and Berger (1982).
* (H) Imipramine binding sites : possible relationship to 5-HT 
uptake sites
Recently there has been increasing interest in investigations 
into the characteristics of imipramine binding sites in both brain 
membrane preparations and on blood platelets. There are probably 
both high- and low-affinity binding sites (Reith et_ al., 1983). The 
high-affinity binding sites in brain tissue are associated with the 
neuronal uptake system for 5-HT (Reith et al., 1983; Rehavi, Skolnick and 
Paul, 1983). There are reports of reduced numbers of imipramine binding 
sites per platelet, though not in the affinity, in depressed patients 
compared with control subjects (Briley et^  al_., 1980; Gay et_ al_., 1983).
A reduction in binding sites, but normal affinity, has also been reported 
for brains of suicides (Stanley, Yirgilio and Gershon, 1982; Perry et al. 
1983). If the imipramine binding site is closely associated with the 
5-HT transport site, then these findings might be taken as validation 
of the use of the platelet as a neuronal model in humans.
(B) INHIBITION OF PLATELET 5-HT UPTAKE BY ANTIDEPRESSANT DRUGS
Platelet 5-HT uptake is inhibited by tricyclic and similar 
antidepressant drugs. Inhibition is caused by interference with 5-IIT 
binding to the transport molecule, reducing the affinity and thereby 
causing an increase in the value of Km of 5-HT uptake. The majority 
of these drugs do not significantly affect , an exception being 
fluvoxamine.
It could be argued that since the rate of 5-HT uptake is 
already reduced in depressive patients, it is illogical to treat 
depression with drugs which reduce 5-HT uptake even further away from 
control values. In addition, the degree of inhibition of 5-HT uptake 
— -does not correlate with clinical state or clinical improvement.
Since completing the work described in Chapter 4, it has been possible 
to assemble results from several clinical trials with 5-HT uptake 
inhibitors and these have been combined, since the correlations presented 
in Chapter 4 may have failed to show significance due to small sample 
size. Platelet 5-HT uptake was measured in samples from a total of 
79 patients who had received an antidepressant drug for either 2 (n = 24) 
or 4 (n = 55 weeks). Baseline drug - free estimations were available
Table 6 .1
Hamilton rating scores and platelet 5“HT uptake 
characteristics of depressed patients before and 
during treatment with an antidepressant drug 1
Results shown as mean + S.E.M. 
with range of values in brackets
Baseline On treatment
n 6k 79
Age (yr1 . kj.2 +1.6
(?0 to 77)
Hamilton Rating Score -20.k +_ O.k 11.6 + 0.T
05 to 31) 0  to 28)
K (yM) 0.5^ +0.03 U.06* + 0.k9
m ~ ~
(0.-2? to 1.15) (0.72 to 2Q.11)
V (pmol/10^ pl/min) ■ . 35 • 5 + 1.8 32.1 +*2.1max . —
(11.0 to 81.6) (.5.1 to 120.k)
y (pmol/10^ pl/mih.) 22.6 + 1. 1 8.8 0.5
(6.0 to. ^ 5.3) (i. 1 to 20.3)
* different from baseline Values, p < 0.0001
+ Antidepressant drugs used were amitriptyline (n = 12), 
clomipramine (n = 11), Imipramine (n = 15), Fluvoxamine (n = 15), 
and zimelidine (n = 26). •
Table 6 .2
Product-moment correlation coefficients between 
clinical improvement and platelet 5~HT uptake 
characteristics in 79 patients treated with 
antidepressant drugs
n Baseline HRS Treatment HRS % Improvement .
Baseline K m
6k +0.209 +0.071 +0.028
Treatment K m - 79
, * 
+0.2l2 +0.150 -0.039
% change K 6k +0.117 -0.005 +0.118
-
Baseline Vmax 6k -O.O89 -0.002 -0.018
Treatment Vmax 79 . +0.021 -o.oll +0.0G0
% change Vmax 6k +0.05^ -0.029 +0.0'(6
Baseline y 6k -0.131 -0.053 -0.010
Treatemnt y 19. -0.167 -0.192 +0.159
% change y 6k -0.091 -0.158 +0.158
*
p < Q.05
for 64 of these patients (Table 6.1}. The antidepressant drugs studied 
were amitriptyline, clomipramine, imipramine, fluvoxamine and zimelidine.
There were no significant correlations between any of the measures 
of clinical improvement (Hamilton rating at 4 weeks, change and percent 
change in Hamilton rating) and any of the values obtained during 
treatment, change from baseline or percent change in K ,-V ^  or y of 
platelet 5-HT uptake (Table 6.2). It could be argued, from the lack 
of significant correlations, that inhibition of 5-HT uptake is of no 
relevance in the treatment of depression.
/
In general, it is found that clinical improvement does not 
correlate with plasma levels of antidopressant drugs. This agrees 
with the results presented here, since 5-HT uptake inhibition was shown 
to be correlated with plasma drug-concentrations, but not with clinical 
improvement. It is possible, though unlikely, that brain concentrations 
of antidepressant drugs are unrelated to plasma drug levels.
It has been suggested that newer drugs, such as zimelidine, 
which inhibit specifically the uptake of a single neurotransmitter 
might prove more effective than the original non-specific inhibitors, 
such as amitriptyline However, the efficacy of zimelidine has been 
shown to be the same as that of amitriptyline rather than being 
superior, in spite of zimelidine being a specific inhibitor of 5-HT 
uptake. The main differences between their actions of clinical 
significance are the much lower incidence of side-effects with zimelidine 
due to the absence of anticholinergic activity, lower cardiac toxicity, 
and lack of interaction with alcohol.
CC) LITHIUM RESTORES 5-HT UPTAKE TO NORMAL IN DEPRESSIVE PATIENTS
—  Both unipolar and bipolar patients receiving lithium carbonate
as a.prophylactic against further episodes of affective illness had 
platelet 5-HT uptake characteristics which did not differ significantly 
from control values. Although the mechanism by which lithium exerts 
its therapeutic effect is not known, it might be supposed that the 
restoration of the rate of 5-HT uptake to normal is a contributing 
factor.
Since it is a monovalent cation, lithium may influence 5-HT 
transport by substituting for either sodium or potassium and thereby
+  4*affecting the activity of Na /K ATPase. There are reports that lithium
+ +
treatment increases. Na /K ATPase activity in erythrocyte membranes 
(Hesketh, 1976; Naylor et al., 1977). .•
(D) COMPARISON OF RESULTS WITH THOSE OF OTHER LABORATORIES
There seems to be general agreement among the reports in the 
literature that platelet 5-HT uptake is reduced in depressed patients 
(Tuomisto, Tukiainen and AhIfors, 1979; Malmgren et al., 1981; Meltzer 
et al., 1981; Stahl et al., 1985). Although most reported values of 
Km are similar, there is a wider variation between reports of the value 
•of Vmax, the values being up to 3 times as high as those reported here. 
Some of the differences between the reports will be due to differences' 
in methodology, including variations in incubation time, incubation 
medium, platelet- concentration and 5-HT concentrations. It is also 
probable that the period over which samples were collected may have 
been only a few months, particularly in those reports on small numbers 
of patients. Due to seasonal variation, samples collected only during 
the winter months would be expected to be significantly higher than 
those collected only in the summer months or regularly over a whole 
year.
It is also possible that differences between the reports 
partly reflect differences between populations, both of depressed 
patients and of control subjects, in different parts of the world.
The diagnosis of the affective disorders, and the classification of 
patients is still a subject for discussion among psychiatrists , with 
cultural variations. Since vulnerability to depression is in part 
genetically determined, it is reasonable to suppose that different 
populations will show differences both in the incidence and the type 
of affective disorder. Similarly, since platelet 5-HT uptake 5s 
dependent on enzyme activity, and therefore might be partly genetically 
determined, it is to be expected that populations will show different 
mean values of platelet 5-HT uptake characteristics.
Since the determination of platelet 5-HT uptake must be carried 
out within a few hours of venepuncture, it would not be possible to
carry out a multi-centre study using one laboratory to compare different 
populations. However, it would be possible to investigate the extent 
of genetic determination of 5-HT transport rates by studying groups of 
blood relatives.
Membrane samples for the determination of affinity and density 
of imipramine binding sites can be stored frozen before assay, hence 
a multicentre study would be possible. If it is proved that the 
imipramine binding site is related to 5-HT transport, then this might 
prove a means of an indirect comparison of 5-HT uptake between 
populations. -
(E) SEASONAL VARIATION IN 5-HT UPTAKE
Control subjects, drug-free depressive patients, and patients '
receiving lithium all showed seasonal variation in the value of V& max
of platelet 5-HT. uptake. All three groups showed a ratio of between
0.6 and 0.7 between their lowest and highest 2-monthly means. The
timing of the peaks and troughs of the three groups did not coincide exactly,
although this is probably not significant. The rate of 5-HT uptake is
lowest in summer and highest in winter. Due to the observed seasonal
variation it is of importance that groups which are to be compared with
respect to their 5-HT uptake characteristics should be samples concurrently.
Lowest rates of platelet 5-HT uptake are observed in late spring 
and early summer. This coincides with the time of year of greatest 
incidence of depression and the peak in the suicide rate. Since the 
variation in day length or photoperiod throughout the year is the most 
regular environmental variable, it is suggested that seasonal variation 
in amount of natural light is a contributing factor in the cause of 
depression. More specifically, a prolonged period of reduced daylight 
hours as experiences in the winter months contributes to the greater 
incidence of depression in the spring : an episode of depressive illness 
characteristically develops over a period of several weeks or months.
This hypothesis is difficult to prove since it would require 
a prospective study of large populations for any variation in incidence 
of depression to be detected. It would require the use of full sunlight 
spretrum light bulbs so that the amount of natural-type light people
are exposed to could be artificially increased. Also the hypothesis 
does not explain the year-round incidence of depression.
Daylength is usually considered to be the circadian basis 
of seasonal biological rhythms (Pittendrigh and Daan, 1976). The 
severity of the symptoms of endogenous depression is generally recognised 
as showing a circadian variation, with the depression of mood being 
at its most severe in the morning and improving towards evening. A 
single experiment using blood samples from one male control subject 
showed no difference in 5-HT uptake between 9 a.m. and a 4 p.m. sample 
(Vmax and Km values both within _+ 5%), it would be worth repeating-with 
groups of controls and depressed patients. Wirz-Justice and Puhringer 
(1978) reported a diurnal rhythm in platelet 5-HT content in both control 
subjects and depressed patients, and a seasonal variation in the diurnal 
rhythm in both groups.
High affinity imipramine binding has been shown to undergo 
circadian variations in rat brain (Wirz-Justice et_ al_., 1983). The 
suprachiasmatic nuclei of the anterior hypothalmus has highest imipramine 
binding at the end of the dark and lowest at the end of the light phase.
A similar circadian rhythm for 5-HT uptake in this region has also been 
observed. A circadian variation in serotonergic turnover in the 
hypothalamus could explain the diurnal variation in mood observed in 
endogenous depression.
■(F): SUGGESTION FOR A POSSIBLE CLINICAL USE THE PLATELET 5-HT UPTAKE ASSAY
Due to the extent of interindividual variation in platelet 5-HT 
uptake, and the overlap in values between controls and depressives, the 
determination of platelet 5-HT uptake characteristics cannot be used in 
the diagnosis of depression, nor for predicting clinical response to 
-antidepressant drug therapy due to the lack of correlation between 5-HT 
uptake and clinical ratings. However, the inhibition of 5-HT uptake 
correlates well with plasma concentrations of drugs. Although inhibition 
of 5-HT uptake does not correlate with efficacy of drug treatment, the 
monitoring of 5-HT uptake may be of use in regulating drug dose, and in 
checking drug-taking compliance. Plasma drug levels generally do not 
correlate with clinical effect, but it is usually accepted that plasma 
drug concentrations which are either very low or very high are of little
benefit. The steady-state plasma concentration obtained with a fixed 
dose regime of antidepressant drugs and their metabolites, which are often 
also of therapeutic benefit, vary widely, up to 30-fold, between patients 
due to variations in metabolism, excretion rates* and induction of 
metabolism by other drugs. The method for the determination of platelet 
5-HT uptake is simple and fairly inexpensive to perform, and results 
can be available within 30 hours of blood sample collection (allowing 
for overnight digestion of platelet pellet at 37°c prior to counting of 
radioactivity : this period could be reduced by incubation for a shorter 
time at a higher temperature).
(G) PLATELET HETEROGENEITY : THE PLATELET-RICH PLASMA VS TOTAL WHOLE 
BLOOD PLATELET SAMPLE CONTROVERSY
One criticism of the method used here, and probably by!all other 
workers to date, for the determination of platelet 5-HT uptake 
characteristics is the method of separating the platelets from the sample 
of whole blood. The preparation of platelet-rich plasma by low speed 
centrifugation does not necessarily yield a truly representative sample 
of the whole blood platelet population, since it is possible that the 
larger platelets are spun down and thus lost from the PRP.
Heavy platelets are up to 1.4 times larger than the smallest 
platelets (Corash, Tan and Gralnick, 1977). The heaviest platelets 
have the same number of mitochondria as the lightest platelets, but 
have up to 3 times as many dense storage granules and are therefore 
able to store more 5-HT. Thus large platelets might be expected to have 
a higher rate of 5-HT uptake. Also, it has been shown, by the injection 
of radiochromium labelled light and heavy platelets, that the large 
platelets have a longer survival time in the circulation, and it is 
concluded that the largest platelets are also the youngest and therefore 
probably also the healthiest (Corash, 1980).
Platelets are produced by fragmentation of megakaryocytes, and 
removed from the circulation by the spleen and liver. Their life span 
in the blood is about 10 days in man. Conditions which affect either 
the rate of production, the life span or the rate of removal of platelets 
from the circulation can be expected to alter the size distribution in 
the platelet population. Thus, it might be argued that since lithium
tends to increase the number of platelets in the circulation this might 
be achieved by stimulating their production, thereby increasing the 
proportion of large, young platelets. This could explain the increased 
rate of platelet 5-HT uptake observed in patients on lithium. It is 
worth noting that a seasonal variation was observed in PRP platelet 
concentration, the trough coinciding with the trough in platelet 5-HT 
uptake. However, it must be remembered the rate of uptake does not 
correlate with the concentration of platelets in PRP, at least within 
the normal population limits.
A second criticism of the method of obtaining the platelet 
sample is that it is possible that the PRP may be contaminated with 
white blood cells, especially if the pipette tip is allowed too near 
'the interface when withdrawing the PRP. Although it is not generally 
considered that the white cells have a system for actively taking up 
5-HT, they may possibly remove some from the plasma during incubation 
by passive diffusion.
It is therefore suggested that the active uptake of 5-HT by 
platelets should be further studied, either using whole blood, or by 
separating the platelets from the whole blood sample by a method which 
recovers better than 95% of the total population.
Preliminary experiments to measure 5-HT uptake by whole blood
have already posed more questions than they have answered. The method
used was as described in Chapter 2, except that whole blood was used
instead of PRP, and the KOH digest was bleached by adding one part digest
to' two parts hydrogen peroxide (20 volumes) in order to prevent quenching
Compared with results of control 5-=HT uptake carried out on PRP
prepared from the same blood samples, the uptake was two to three times
higher in whole blood. The rate of uptake was sufficiently great to
14cause significant reductions in the amount of free C-5-.HT within the 
2 minute incubation period. Subsequently, time course experiments 
showed that the rate of uptake in whole blood had declined significantly 
from the initial rate by 2 minutes. It is possible that incubation times 
of 30 seconds or less may be required for whole blood 5-HT uptake 
experiments. It will be interesting to study this further : is the 
difference in uptake rates between whole blood and PRP preparations 
real, and if so why : do other blood cells take up 5-HT?Although the
red and white cells are not able to store 5-HT as platelets do, they 
may still remove small amounts from the plasma, even if it is immediately 
released again. By sheer weight of numbers, the red cells would each 
only need to take up very little to make a large difference to the 
apparent results.
There are two fairly simple methods for removing a total platelet 
population from other whole blood constituents. One Is by density 
gradient centrifugation, using a product such as Ficoll. The other 
which is marginally easier to perform (density gradient methods require 
a steady hand!), is a sequence of dilution/low speed centrifugations. 
Briefly, 5ml of blood is mixed with 2ml of phosphate buffered saline 
glucose solution, the mixture centrifuged at 600 x g  for 3 minutes, and 
the supernatant portion removed. The volume of the residual red cell 
platelet is made up to 7ml with buffer, and then centrifuged again.
After 5 washes the pooled supernatant fractions should contain at 
least 95% of the total platelet population (Corash, 1980).
It is possible that the observed differences in platelet 5-HT 
uptake rates between control subjects and depressive patients may be 
due to differences between the groups in their platelet population 
structure. Using the Corash method, 5-HT uptake determinations might 
be done on platelet samples which are accurate representatives of the 
total platelet population. Alternatively, the total platelet 
populations obtained might be sub-divided into three or four fractions 
according to size, and the proportions of larger and smaller platelets 
determined and their 5-HT uptake rates compared for the different groups.
(E) SUMMARY
The work described in this thesis has provided further evidence 
that an abnormality of 5-HT turnover is an important factor in the 
aetiology of depressive illness. The rate of platelet 5-HT uptake is 
significantly lower in depressive patients that control subjects.
If the platelet is valid model for the serotonergic neurone, then 
depressive patients have an impairment of the transmission of 5-HT 
across the synapse.
The measurement of platelet 5-HT uptake characteristics has
been shown to be of use in the investigation of the effects of antidepressant 
drugs. The method can be used (1) to compare the potency of different 
drugs as 5-HT uptake inhibitors; (2) as a guide to plasma drug 
concentrations and allow thereby for dosage adjustment to maintain 
adequate drug levels; and (3) as a test of compliance in patients 
receiving 5-HT uptake inhibitors.
Platelet 5-HT uptake characteristics by themselves cannot be 
used to confirm a diagnosis of depressive illness, due to overlap 
between patient and control values. However, it might be of use in 
diagnosis if taken in conjunction with other biological measures, for 
example the dexamethasone suppression test (Carroll, 1982; Meltzer et al., 
1983), or analysis' of erythrocyte membrane polyunsaturated fatty acids 
(Fehily, 1980). Although the majority of cases of depressive illness 
do not require laboratory confirmation, there are a few cases which 
are difficult to diagnose on clinical data alone, and for these cases 
a confirmation of" diagnosis would be useful as a guide to treatment. 
Biochemical confirmation of diagnosis is also of use in multicentre 
trials and investigations into depressive illness and its treatment, 
especially where results from different countries and cultures are to 
be combined.
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